_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
502540300,7/11/2014 23:53:21,,1321074821,7/11/2014 23:53:03,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],defined,n/a,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 00:04:01,,1321080494,7/12/2014 00:02:53,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[IS_A],[IS_A],is defined as:,n/a,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 00:07:10,,1321082343,7/12/2014 00:06:34,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],hypertension,not sure,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 00:36:08,,1321098346,7/12/2014 00:35:11,instagc,1,13763729,USA,,,75.182.89.225,[IS_A],[IS_A],RELATED BLOOD PRESSURE/HYPERTENSION ELEVATED BLOOD PRESSURE,N/A,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 00:51:54,,1321104806,7/12/2014 00:50:47,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[SYMPTOM],[SYMPTOM],history,not applicable,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 01:19:01,,1321115718,7/12/2014 01:18:24,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[IS_A],[IS_A],RELATED BLOOD PRESSURE/HYPERTENSION is defined as: ELEVATED BLOOD PRESSURE,N/A,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 01:34:31,,1321122489,7/12/2014 01:34:04,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[CONTRAINDICATES],[CONTRAINDICATES],defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE,n/a,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 01:50:58,,1321127102,7/12/2014 01:49:41,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OC RELATED BLOOD PRESSURE/HYPERTENSION ELEVATED BLOOD PRESSURE,n/a,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 01:58:14,,1321130071,7/12/2014 01:57:04,prodege,1,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],OC RELATED BLOOD PRESSURE/HYPERTENSION defined as: women with neither nor ELEVATED BLOOD PRESSURE,N/A,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 02:09:41,,1321134414,7/12/2014 02:08:31,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],is defined as:,Its just a definition,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 03:59:08,,1321176700,7/12/2014 03:58:21,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[CAUSES],[CAUSES],RELATED BLOOD PRESSURE/HYPERTENSION ELEVATED BLOOD PRESSURE,N/A,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 04:50:18,,1321195542,7/12/2014 04:48:46,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],RELATED BLOOD PRESSURE/HYPERTENSION is defined as: ELEVATED BLOOD PRESSURE,N/A,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 06:17:19,,1321224835,7/12/2014 06:16:19,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[IS_A],[IS_A],defined as:,n/a,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 06:19:09,,1321225506,7/12/2014 06:17:53,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],defined as:,N/A,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540300,7/12/2014 07:43:36,,1321255088,7/12/2014 07:41:41,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],defined develop,N/A,101,3,124,38,-1,RO-has_definitional_manifestation,904916-FS1,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
502540301,7/12/2014 00:10:09,,1321084151,7/12/2014 00:09:51,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[TREATS],[TREATS],Treatment with and,n/a,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 00:10:43,,1321084484,7/12/2014 00:10:31,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],Treatment,n/a,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 00:42:20,,1321101178,7/12/2014 00:41:49,instagc,1,13763729,USA,,,75.182.89.225,[OTHER],[OTHER],Treatment of REFRACTORY DIARRHOEA with OCTREOTIDE:,N/A,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 00:51:15,,1321104588,7/12/2014 00:50:10,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with acetorphan,with acetorphan,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 01:01:13,,1321108537,7/12/2014 01:00:49,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],Treatment,not applicable,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 01:21:36,,1321116696,7/12/2014 01:20:54,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",Treatment of REFRACTORY DIARRHOEA with OCTREOTIDE:,N/A,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 01:53:16,,1321128115,7/12/2014 01:52:10,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],REFRACTORY DIARRHOEA OCTREOTIDE:,n/a,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 01:58:41,,1321130273,7/12/2014 01:57:59,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],Treatment,n/a,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 03:32:34,,1321166082,7/12/2014 03:31:48,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],Treatment of REFRACTORY DIARRHOEA with OCTREOTIDE:,treats,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 03:36:33,,1321167778,7/12/2014 03:36:21,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],Treatment,N/A,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 03:43:47,,1321170439,7/12/2014 03:43:25,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS],[TREATS],Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE:,N/A,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 04:05:36,,1321179640,7/12/2014 04:04:42,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[SYMPTOM],[SYMPTOM],REFRACTORY DIARRHOEA with acetorphan OCTREOTIDE:,N/A,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 05:06:41,,1321201280,7/12/2014 05:06:07,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],Treatment REFRACTORY DIARRHOEA with OCTREOTIDE:,N/A,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 07:53:38,,1321258301,7/12/2014 07:52:29,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],Treatment with,n/a,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540301,7/12/2014 08:20:33,,1321266614,7/12/2014 08:20:08,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],Treatment,N/A,13,62,33,72,1,RO-may_treat,907795-FS1,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
502540302,7/11/2014 23:51:40,,1321073901,7/11/2014 23:50:11,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[OTHER],[OTHER],related,n/a,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/11/2014 23:55:53,,1321076030,7/11/2014 23:55:12,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],may occur,n/a,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 00:04:22,,1321080743,7/12/2014 00:04:02,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related to,n/a,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 00:09:54,,1321083995,7/12/2014 00:09:16,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],occur,N/AN/A,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 00:36:19,,1321098419,7/12/2014 00:35:41,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],may be related to,N/A,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 01:12:12,,1321113020,7/12/2014 01:11:36,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",may occur,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 01:28:35,,1321119804,7/12/2014 01:27:54,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[SIDE_EFFECT],[SIDE_EFFECT],RIBOFLAVIN DEFICIENCY related to RIBOFLAVIN,N/A,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 01:31:25,,1321121072,7/12/2014 01:31:02,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],deficiency may be related to dietary intake,n/a,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 02:11:55,,1321135275,7/12/2014 02:10:54,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RIBOFLAVIN DEFICIENCY RIBOFLAVIN,n/a,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 02:15:26,,1321136998,7/12/2014 02:14:39,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[MANIFESTATION],[MANIFESTATION],may be related,This sickness may be linked/related to another sickness,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 03:08:08,,1321156792,7/12/2014 03:06:54,instagc,1,13763729,USA,,,75.182.89.225,[SYMPTOM],[SYMPTOM],RIBOFLAVIN DEFICIENCY may occur in adolescents deficiency related to dietary intake RIBOFLAVIN,N/A,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 03:35:27,,1321167300,7/12/2014 03:35:11,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[CAUSES],[CAUSES],related,N/A,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 04:01:05,,1321177685,7/12/2014 04:00:16,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RIBOFLAVIN DEFICIENCY occur adolescents deficiency may be related to dietary intake RIBOFLAVIN,associated with,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 04:04:41,,1321179245,7/12/2014 04:03:59,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[CAUSES],[CAUSES],RIBOFLAVIN DEFICIENCY may occur deficiency RIBOFLAVIN,N/A,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540302,7/12/2014 04:58:28,,1321198134,7/12/2014 04:57:42,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[PREVENTS],[PREVENTS],RIBOFLAVIN DEFICIENCY may be related to dietary intake of RIBOFLAVIN,N/A,36,36,57,46,1,RO-may_prevent,907355-FS1,These data suggest that subclinical RIBOFLAVIN DEFICIENCY may occur in adolescents and that deficiency may be related to dietary intake of RIBOFLAVIN,RIBOFLAVIN DEFICIENCY,RIBOFLAVIN
502540303,7/12/2014 00:07:43,,1321082668,7/12/2014 00:07:22,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],for the treatment of,N/A,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 00:39:10,,1321099697,7/12/2014 00:38:10,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treatment,not applicable,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 00:43:24,,1321101616,7/12/2014 00:42:49,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[TREATS],[TREATS],treatment,Na,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 00:59:50,,1321107973,7/12/2014 00:59:02,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",Comparison of the angiotensin II receptor,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 01:18:24,,1321115520,7/12/2014 01:17:48,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",ATENOLOL treatment of HYPERTENSION,N/A,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 01:52:03,,1321127514,7/12/2014 01:51:03,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],ATENOLOL HYPERTENSION,n/a,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 02:29:13,,1321143062,7/12/2014 02:26:47,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],for the treatment of,n/a,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 03:04:31,,1321155464,7/12/2014 03:03:02,instagc,1,13763729,USA,,,75.182.89.225,[OTHER],[OTHER],ATENOLOL for the treatment of HYPERTENSION,Hypertension is treated with Atenolol.,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 03:59:21,,1321176770,7/12/2014 03:58:40,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],ATENOLOL for the treatment of HYPERTENSION,treats,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 04:00:44,,1321177537,7/12/2014 04:00:11,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[TREATS],[TREATS],ATENOLOL treatment HYPERTENSION,N/A,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 06:15:06,,1321224001,7/12/2014 06:14:34,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[TREATS],[TREATS],treatment,n/a,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 06:32:05,,1321230117,7/12/2014 06:31:37,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],for the treatment of,N/A,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 08:04:59,,1321262089,7/12/2014 08:03:48,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment of,n/a,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 08:05:29,,1321262219,7/12/2014 08:05:12,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],treatment,n/a,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540303,7/12/2014 08:20:59,,1321266772,7/12/2014 08:20:34,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treatment,N/A,145,115,157,123,1,RO-may_treat,907512-FS1,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
502540304,7/12/2014 00:04:51,,1321081031,7/12/2014 00:04:42,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],no thyroid,not sure,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 00:36:08,,1321098326,7/12/2014 00:35:31,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],without GOITER,n/a,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 01:11:32,,1321112664,7/12/2014 01:10:55,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were divided,[DIAGNOSE_BY_TEST_OR_DRUG],278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 01:23:25,,1321117413,7/12/2014 01:22:37,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",without GOITER THYROIDitis:,N/A,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 01:55:24,,1321128979,7/12/2014 01:54:05,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],position,n/a,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 02:00:06,,1321130661,7/12/2014 01:58:55,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GOITER THYROIDitis:,n/a,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 02:06:08,,1321133016,7/12/2014 02:03:59,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],divided into 6 groups:,There was not relation option that matched the sentence,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 03:33:05,,1321166334,7/12/2014 03:32:17,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[NONE],[NONE],N/A,I cannot find a relation.,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 05:00:25,,1321198675,7/12/2014 04:58:29,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[SIDE_EFFECT],[SIDE_EFFECT],GOITER in ectopic position THYROIDitis:,N/A,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 06:21:20,,1321226245,7/12/2014 06:20:51,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PART_OF],[PART_OF],divided into 6 groups:,N/A,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 08:01:16,,1321261010,7/12/2014 07:59:03,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],divided,N/A,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 08:02:12,,1321261248,7/12/2014 08:01:46,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[OTHER],[OTHER],divided into groups:,n/a,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 08:17:52,,1321265661,7/12/2014 08:16:43,clixsense,1,6336109,CAN,ON,Pontypool,204.237.91.84,[ASSOCIATED_WITH],[ASSOCIATED_WITH],hypothyroid without GOITER,N/A,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 08:21:55,,1321267092,7/12/2014 08:21:47,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],iodine,da,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540304,7/12/2014 08:24:50,,1321268016,7/12/2014 08:24:21,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],without,n/a,278,42,285,48,1,RO-disease_has_primary_anatomic_site,902026-FS1,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
502540305,7/12/2014 00:03:46,,1321080319,7/12/2014 00:03:28,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],WEIGHT,not sure,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 00:13:22,,1321086006,7/12/2014 00:12:43,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],65% had,N/A,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 00:32:15,,1321096284,7/12/2014 00:31:37,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],had,n/a,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 00:45:55,,1321102574,7/12/2014 00:45:12,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[SIDE_EFFECT],[SIDE_EFFECT],"WEIGHT LOSS abdominal masses,",not applicable,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 02:23:18,,1321140803,7/12/2014 02:21:09,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[SYMPTOM],[SYMPTOM],had,n/a,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 03:29:46,,1321165287,7/12/2014 03:28:54,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],LYMPHOMA PATIENTS WITHOUT IPSID 65% had WEIGHT LOSS,symptom,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 03:32:21,,1321166037,7/12/2014 03:32:07,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[SYMPTOM],[SYMPTOM],had,N/A,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 03:55:10,,1321175094,7/12/2014 03:53:49,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[CAUSES],[CAUSES],"LYMPHOMA PATIENTS WITHOUT IPSID had abdominal pain, WEIGHT",because LYMPHOMA PATIENTS had weight loss,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 04:47:46,,1321194904,7/12/2014 04:46:53,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],LYMPHOMA PATIENTS WITHOUT IPSID had WEIGHT LOSS,N/A,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 06:10:33,,1321222517,7/12/2014 06:07:32,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],had,N/A,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 07:50:14,,1321257097,7/12/2014 07:49:52,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],had,n/a,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 08:06:14,,1321262497,7/12/2014 08:05:54,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[PREVENTS],[PREVENTS],WITHOUT IPSID 65% abdominal,n/a,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 08:19:12,,1321266086,7/12/2014 08:17:38,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],WITHOUT,N/A,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 08:20:42,,1321266657,7/12/2014 08:20:37,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],LYMPHOMA,da,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540305,7/12/2014 08:37:11,,1321272287,7/12/2014 08:36:34,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]","had abdominal pain, WEIGHT LOSS",n/a,66,10,77,41,-1,RO-disease_may_have_finding,902589-FS1,"Among the LYMPHOMA PATIENTS WITHOUT IPSID 65% had abdominal pain, WEIGHT LOSS abdominal masses, obstruction, and perforation.",WEIGHT LOSS,LYMPHOMA PATIENTS WITHOUT IPSID
502540306,7/11/2014 23:53:01,,1321074594,7/11/2014 23:52:39,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],for,n/a,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 00:07:30,,1321082549,7/12/2014 00:06:47,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATROPINE BRADYCARDIA,n/a,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 00:28:28,,1321094336,7/12/2014 00:27:45,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[PREVENTS],[PREVENTS],for,n/a,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 00:33:05,,1321096803,7/12/2014 00:32:30,instagc,1,13763729,USA,,,75.182.89.225,[OTHER],[OTHER],ATROPINE for BRADYCARDIA,N/A,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 00:41:02,,1321100494,7/12/2014 00:39:11,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],for,not applicable,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 01:20:54,,1321116472,7/12/2014 01:20:16,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",ATROPINE for BRADYCARDIA,N/A,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 01:54:12,,1321128554,7/12/2014 01:52:55,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],multiple dose activated,this could be under the topic information,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 01:56:16,,1321129367,7/12/2014 01:55:03,prodege,1,17334212,CAN,NB,Fredericton,142.162.42.73,[TREATS],[TREATS],Maintenance of ATROPINE for BRADYCARDIA,N/A,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 02:08:26,,1321133897,7/12/2014 02:07:28,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],ATROPINE BRADYCARDIA,n/a,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 03:28:38,,1321164926,7/12/2014 03:28:14,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],for,N/A,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 03:49:24,,1321172593,7/12/2014 03:48:02,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],or isoproterenol for,na,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 04:01:39,,1321177926,7/12/2014 04:00:45,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATROPINE isoproterenol BRADYCARDIA,N/A,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 05:03:49,,1321200016,7/12/2014 05:02:59,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],ATROPINE for BRADYCARDIA,N/A,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 07:54:45,,1321258729,7/12/2014 07:54:11,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[PART_OF],[PART_OF],"breathing, circulation; ATROPINE isoproterenol",n/a,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540306,7/12/2014 08:03:46,,1321261786,7/12/2014 08:02:40,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],for,n/a,233,203,244,211,1,RO-may_treat,907917-FS1,"Maintenance of airway, breathing, and circulation; fluids and vasopressors for hypotension; multiple dose activated charcoal; calcium chloride or calcium gluconate for hypotension and bradydysrhythmias, ATROPINE or isoproterenol for BRADYCARDIA",BRADYCARDIA,ATROPINE
502540307,7/11/2014 23:53:41,,1321074998,7/11/2014 23:51:44,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[CAUSES],[CAUSES],may be caused by,n/a,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 00:11:37,,1321084980,7/12/2014 00:11:30,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],important,N/A,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 00:28:14,,1321094216,7/12/2014 00:27:55,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],caused by,N/A,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 00:44:06,,1321101871,7/12/2014 00:43:26,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[CAUSES],[CAUSES],caused by,Na,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 00:53:42,,1321105635,7/12/2014 00:53:23,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES],[CAUSES],caused by,not applicable,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 01:13:47,,1321113783,7/12/2014 01:13:01,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],may be caused by,[CAUSES],43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 01:24:54,,1321118049,7/12/2014 01:23:58,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],FUNGAL INFECTIONS caused by FUNGI,N/A,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 01:32:52,,1321121757,7/12/2014 01:32:34,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[CAUSES],[CAUSES],may be caused by several FUNGI,n/a,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 01:51:39,,1321127375,7/12/2014 01:51:05,prodege,1,17334212,CAN,NB,Fredericton,142.162.42.73,[CAUSES],[CAUSES],FUNGAL INFECTIONS may be caused by several FUNGI,N/A,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 02:24:17,,1321141190,7/12/2014 02:23:26,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[CAUSES],[CAUSES],FUNGAL INFECTIONS may be caused,FUNGAL INFECTIONS may be cause by this [subject],43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 03:27:59,,1321164737,7/12/2014 03:27:29,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES],[CAUSES],FUNGAL INFECTIONS may be caused by several FUNGI,N/A,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 03:28:54,,1321165014,7/12/2014 03:28:39,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[CAUSES],[CAUSES],caused,N/A,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 03:58:39,,1321176432,7/12/2014 03:57:49,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",FUNGAL INFECTIONS may caused several FUNGI,part of/associated with,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 04:10:14,,1321181748,7/12/2014 04:09:24,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[CAUSES],[CAUSES],FUNGAL INFECTIONS caused FUNGI,N/A,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540307,7/12/2014 04:46:52,,1321194633,7/12/2014 04:46:11,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],FUNGAL INFECTIONS may be caused by FUNGI,N/A,43,0,48,17,1,RO-has_causative_agent,903639-FS1,"FUNGAL INFECTIONS may be caused by several FUNGI the most important of these being Candida species including C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondii.",FUNGI,FUNGAL INFECTIONS
502540308,7/11/2014 23:55:10,,1321075640,7/11/2014 23:54:45,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],may have higher risk of,n/a,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 00:11:39,,1321084983,7/12/2014 00:11:25,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have,n/a,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 00:54:12,,1321105832,7/12/2014 00:53:43,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[SIDE_EFFECT],[SIDE_EFFECT],higher risk,not applicable,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 01:05:17,,1321110140,7/12/2014 01:04:35,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],may have higher risk,[DIAGNOSE_BY_TEST_OR_DRUG],27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 01:26:29,,1321118759,7/12/2014 01:25:49,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",BEESTING ALLERGY have higher risk of HYPERSENSITIVITY REACTION,N/A,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 02:11:33,,1321135182,7/12/2014 02:09:42,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],Patients with a history of BEESTING ALLERGY may have a higher risk of,if patients with beesting allergy they may have a higher risk.,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 03:05:49,,1321155879,7/12/2014 03:05:12,instagc,1,13763729,USA,,,75.182.89.225,[CAUSES],[CAUSES],BEESTING ALLERGY higher risk of a HYPERSENSITIVITY REACTION,N/A,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 03:19:54,,1321161520,7/12/2014 03:18:00,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES] [ASSOCIATED_WITH] [TREATS],"[TREATS]
[CAUSES]
[ASSOCIATED_WITH]",BEESTING ALLERGY may have higher risk of HYPERSENSITIVITY REACTION with paclitaxel treatment.,N/A,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 03:35:56,,1321167533,7/12/2014 03:35:43,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[CAUSES],[CAUSES],higher risk,N/A,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 03:36:15,,1321167669,7/12/2014 03:35:08,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[CONTRAINDICATES],[CONTRAINDICATES],history BEESTING ALLERGY higher risk HYPERSENSITIVITY REACTION paclitaxel,contraindicates,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 03:39:36,,1321168780,7/12/2014 03:38:02,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],may have a higher risk of a,na,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 04:05:59,,1321179846,7/12/2014 04:05:37,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[CAUSES],[CAUSES],BEESTING ALLERGY HYPERSENSITIVITY REACTION,N/A,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 04:55:35,,1321197325,7/12/2014 04:54:50,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION,N/A,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 06:27:30,,1321228356,7/12/2014 06:27:02,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with a history of,N/A,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540308,7/12/2014 07:55:09,,1321258909,7/12/2014 07:54:46,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[SYMPTOM],[SYMPTOM],BEESTING ALLERGY treatment.,n/a,27,72,43,97,-1,RO-cause_of,900406-FS1,Patients with a history of BEESTING ALLERGY may have a higher risk of a HYPERSENSITIVITY REACTION with paclitaxel treatment.,BEESTING ALLERGY,HYPERSENSITIVITY REACTION
502540309,7/12/2014 00:01:53,,1321079235,7/12/2014 00:01:28,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],and,n/a,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 00:03:57,,1321080420,7/12/2014 00:03:47,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],duration,not sure,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 00:10:43,,1321084500,7/12/2014 00:09:35,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship from this sentence.,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 01:57:25,,1321129824,7/12/2014 01:56:22,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,two different issues,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 03:06:53,,1321156296,7/12/2014 03:05:50,instagc,1,13763729,USA,,,75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],role of LEU in sensomotor cortex limitation intensity duration of SEIZURES prevention of STATUS EPILEPTICUS,N/A,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 03:34:13,,1321166667,7/12/2014 03:32:34,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],duration SEIZURES prevention STATUS EPILEPTICUS,associated with,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 03:37:49,,1321168148,7/12/2014 03:37:10,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[SYMPTOM],[SYMPTOM],A possible role of LEU is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,N/A,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 03:43:48,,1321170440,7/12/2014 03:43:08,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES and prevention of STATUS EPILEPTICUS,na,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 04:53:02,,1321196510,7/12/2014 04:51:51,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],SEIZURES and prevention of STATUS EPILEPTICUS,N/A,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 06:24:06,,1321227162,7/12/2014 06:23:33,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 07:59:18,,1321260281,7/12/2014 07:59:02,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[PREVENTS],[PREVENTS],prevention,n/a,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 08:17:37,,1321265589,7/12/2014 08:17:10,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],prevention,N/A,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 08:22:10,,1321267160,7/12/2014 08:22:03,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[SYMPTOM],[SYMPTOM],sensomotor,da,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 08:25:24,,1321268302,7/12/2014 08:24:51,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],limitation intensity and prevention of,n/a,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540309,7/12/2014 08:32:51,,1321271057,7/12/2014 08:32:13,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prevention of,n/a,87,114,95,132,-1,RO-has_definitional_manifestation,904608-FS1,A possible role of LEU in sensomotor cortex is limitation of intensity and duration of SEIZURES and prevention of STATUS EPILEPTICUS,SEIZURES,STATUS EPILEPTICUS
502540310,7/12/2014 00:07:21,,1321082437,7/12/2014 00:06:57,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],therapeutic effects of,N/A,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 00:08:46,,1321083269,7/12/2014 00:08:24,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],therapeutic effects,n/a,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 00:17:08,,1321088270,7/12/2014 00:16:20,instagc,1,13763729,USA,,,75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],therapeutic effects of CLOZAPINE in SCHIZOPHRENIA,N/A,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 00:30:31,,1321095407,7/12/2014 00:29:58,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may be related,n/a,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 00:55:16,,1321106277,7/12/2014 00:54:38,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[SIDE_EFFECT],[SIDE_EFFECT],therapeutic effects,not applicable,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 01:29:10,,1321120029,7/12/2014 01:28:36,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],the therapeutic effects,n/a,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 01:56:20,,1321129387,7/12/2014 01:55:50,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],therapeutic effects,n/a,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 03:28:54,,1321165001,7/12/2014 03:28:00,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],therapeutic effects CLOZAPINE and perhaps SCHIZOPHRENIA,treats,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 03:29:20,,1321165157,7/12/2014 03:28:00,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.,N/A,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 03:59:44,,1321177005,7/12/2014 03:59:06,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],therapeutic effects of CLOZAPINE,na,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 04:08:28,,1321180896,7/12/2014 04:07:58,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[TREATS],[TREATS],therapeutic effects CLOZAPINE SCHIZOPHRENIA,N/A,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 04:44:51,,1321193775,7/12/2014 04:43:43,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA,N/A,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 07:57:58,,1321259780,7/12/2014 07:57:33,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],support effects,n/a,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 08:00:46,,1321260845,7/12/2014 08:00:23,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],therapeutic effects,n/a,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540310,7/12/2014 08:07:52,,1321262954,7/12/2014 08:05:42,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],CLOZAPINE,N/A,125,78,138,87,1,RO-may_treat,908293-FS1,"Thus, the present data support the hypothesis that the therapeutic effects of CLOZAPINE in this primate model and perhaps in SCHIZOPHRENIA may be related at least in part to the restoration of DA tone in the prefrontal cortex.",SCHIZOPHRENIA,CLOZAPINE
502540311,7/12/2014 00:09:08,,1321083520,7/12/2014 00:08:17,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 00:56:13,,1321106656,7/12/2014 00:55:19,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[SYMPTOM] [SIDE_EFFECT] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]
[SIDE_EFFECT]",consider,[SYMPTOM] [SIDE_EFFECT] [ASSOCIATED_WITH],136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 00:56:58,,1321106959,7/12/2014 00:56:15,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],consider,not applicable,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 01:32:21,,1321121518,7/12/2014 01:31:37,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],OPIOID OVERDOSE; consider FLUMAZENIL,N/A,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 01:52:31,,1321127743,7/12/2014 01:51:40,prodege,1,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],Give naloxone for OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose,N/A,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 01:58:38,,1321130256,7/12/2014 01:57:29,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OPIOID OVERDOSE; FLUMAZENIL,n/a,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 02:03:57,,1321132161,7/12/2014 02:03:08,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],N/A,This is just a list of something?,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 02:35:41,,1321145296,7/12/2014 02:34:17,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,flumazenil is to be considered for something else,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 03:10:06,,1321157653,7/12/2014 03:08:59,instagc,1,13763729,USA,,,75.182.89.225,[NONE],[NONE],N/A,"One is a drug used to treat another illness, the other is a different illness.",136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 03:31:23,,1321165732,7/12/2014 03:30:57,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],consider,N/A,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 03:37:11,,1321167937,7/12/2014 03:36:02,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],consider FLUMAZENIL,na,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 03:44:31,,1321170693,7/12/2014 03:43:49,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[NONE],[NONE],N/A,I cannot find a relation(s).,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 05:02:35,,1321199415,7/12/2014 05:01:01,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],none,They are not related; only mentioned in the same report.,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 07:57:16,,1321259582,7/12/2014 07:56:52,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],Give naloxone,n/a,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540311,7/12/2014 08:02:56,,1321261500,7/12/2014 08:01:18,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],overdose,N/A,136,162,151,172,1,RO-may_treat,907481-FS1,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
502540312,7/12/2014 00:02:21,,1321079482,7/12/2014 00:00:55,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in therapy with,n/a,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 00:09:14,,1321083550,7/12/2014 00:07:12,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],patients,not sure,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 00:12:41,,1321085633,7/12/2014 00:12:21,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],in therapy with,N/A,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 00:33:58,,1321097235,7/12/2014 00:33:06,instagc,1,13763729,USA,,,75.182.89.225,[OTHER],[OTHER],RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40,N/A,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 00:45:11,,1321102291,7/12/2014 00:44:34,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],therapy,not applicable,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 01:36:34,,1321123249,7/12/2014 01:36:08,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB,N/A,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 02:17:38,,1321138046,7/12/2014 02:16:13,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],study observed in clinical practice.,This is a study/research,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 02:23:45,,1321140963,7/12/2014 02:23:18,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],therapy with,n/a,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 02:37:10,,1321145756,7/12/2014 02:36:28,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],RHEUMATOID ARTHRITIS ADALIMUMAB 40 mg,n/a,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 03:50:29,,1321173030,7/12/2014 03:49:25,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],in therapy with,na,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 04:02:15,,1321178152,7/12/2014 04:01:40,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[TREATS],[TREATS],RHEUMATOID ARTHRITIS therapy ADALIMUMAB,N/A,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 05:10:56,,1321202973,7/12/2014 05:09:53,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],RHEUMATOID ARTHRITIS therapy with ADALIMUMAB 40 mg every other week,treats,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 07:51:23,,1321257542,7/12/2014 07:50:15,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],in therapy with,n/a,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 07:53:13,,1321258136,7/12/2014 07:51:19,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],clinical practice.,N/A,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540312,7/12/2014 08:00:41,,1321260806,7/12/2014 08:00:17,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[OTHER],[OTHER],study,n/a,88,125,108,135,1,RO-may_treat,908133-FS1,The objective of this study is to perform a cost effective analysis of 86 patients with RHEUMATOID ARTHRITIS in therapy with ADALIMUMAB 40 mg every other week and etanercept 50 mg/week for two years in a population of patients observed in clinical practice.,RHEUMATOID ARTHRITIS,ADALIMUMAB
502540313,7/12/2014 00:04:09,,1321080574,7/12/2014 00:03:59,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],SYNOPHRYS,not sure,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 00:35:07,,1321097757,7/12/2014 00:34:45,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 00:57:41,,1321107216,7/12/2014 00:56:59,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,not applicable,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 01:00:46,,1321108308,7/12/2014 00:59:53,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",showed,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 01:16:36,,1321114890,7/12/2014 01:15:48,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],CORNELIA DE LANGE SYNDROME with SYNOPHRYS,N/A,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 01:30:43,,1321120748,7/12/2014 01:30:11,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],with,n/a,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 02:30:46,,1321143610,7/12/2014 02:29:14,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],with,n/a,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 02:30:53,,1321143632,7/12/2014 02:29:55,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],CORNELIA DE LANGE SYNDROME SYNOPHRYS,n/a,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 03:59:05,,1321176654,7/12/2014 03:58:16,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[SYMPTOM],[SYMPTOM],characteristic facies of,na,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 04:54:48,,1321197078,7/12/2014 04:53:33,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CORNELIA DE LANGE SYNDROME with SYNOPHRYS,N/A,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 05:00:59,,1321198844,7/12/2014 04:59:46,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],characteristic facies the CORNELIA DE LANGE SYNDROME with SYNOPHRYS,symptom,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 06:17:51,,1321225052,7/12/2014 06:17:17,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SIDE_EFFECT],[SIDE_EFFECT],"long curly eyelashes small upturned nose, physical features,",N/A,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 08:09:19,,1321263386,7/12/2014 08:08:53,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],characteristic facies,n/a,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 08:16:33,,1321265305,7/12/2014 08:15:32,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540313,7/12/2014 08:22:23,,1321267220,7/12/2014 08:22:18,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],including,da,85,53,94,79,1,RO-has_manifestation,906277-FS1,"The patients showed the characteristic facies of the CORNELIA DE LANGE SYNDROME with SYNOPHRYS long curly eyelashes and small upturned nose, and physical features, including generalized hirsutism, monodactyly, syndactyly and clinodactyly.",SYNOPHRYS,CORNELIA DE LANGE SYNDROME
502540314,7/11/2014 23:52:39,,1321074386,7/11/2014 23:51:41,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],analgesic,n/a,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 00:08:10,,1321082908,7/12/2014 00:07:53,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],analgesic,n/a,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 00:35:10,,1321097800,7/12/2014 00:34:33,instagc,1,13763729,USA,,,75.182.89.225,[OTHER],[OTHER],GLUCOSAMINE SULPHATE analgesic in OSTEOARTHRITIS OF THE KNEE,N/A,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 00:38:28,,1321099376,7/12/2014 00:37:39,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[TREATS],[TREATS],analgesic in,Na,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 01:57:58,,1321129968,7/12/2014 01:57:26,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],analgesic,n/a,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 02:23:26,,1321140837,7/12/2014 02:22:51,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],N/A,This is related to nothing,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 03:35:10,,1321167137,7/12/2014 03:34:54,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],analgesic,N/A,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 03:45:48,,1321171229,7/12/2014 03:44:32,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS],[TREATS],treatments for osteoarthritis Arthritis,N/A,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 04:12:07,,1321182720,7/12/2014 04:11:16,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[TREATS],[TREATS],GLUCOSAMINE SULPHATE OSTEOARTHRITIS OF THE KNEE,N/A,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 05:03:44,,1321199944,7/12/2014 05:02:37,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],GLUCOSAMINE SULPHATE an analgesic in OSTEOARTHRITIS OF THE KNEE,treats,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 05:04:34,,1321200351,7/12/2014 05:03:51,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE,N/A,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 06:14:33,,1321223785,7/12/2014 06:13:05,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[TREATS],[TREATS],treatments,n/a,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 06:33:03,,1321230365,7/12/2014 06:32:07,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],as an analgesic in,N/A,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 07:51:18,,1321257521,7/12/2014 07:48:30,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],placebo trial,N/A,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540314,7/12/2014 07:54:59,,1321258854,7/12/2014 07:53:41,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],as an analgesic in,N/A,550,510,576,530,1,RO-may_treat,907762-FS1,"trial  Lancet  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  New England Journal of Medicine  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis  Osteoarthritis and Cartilage  A randomized, placebo controlled, cross over study of ginger extracts and ibuprofen in osteoarthritis  Rheumatic Diseases Clinics of North America  Homeopathy and rheumatic disease  Rheumatology (Oxford)  A randomized, double blind, placebo controlled trial of GLUCOSAMINE SULPHATE as an analgesic in OSTEOARTHRITIS OF THE KNEE  Review  Alternative Medicine Review  Natural treatments for osteoarthritis  Arthritis and.",OSTEOARTHRITIS OF THE KNEE,GLUCOSAMINE SULPHATE
502540315,7/11/2014 23:54:49,,1321075484,7/11/2014 23:54:02,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],development,n/a,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 00:05:12,,1321081178,7/12/2014 00:04:24,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],are development,n/a,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 00:08:15,,1321082979,7/12/2014 00:07:44,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],protected from the development of,N/A,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 00:09:05,,1321083508,7/12/2014 00:08:49,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],development,n/a,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 00:46:50,,1321102936,7/12/2014 00:45:56,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[PREVENTS],[PREVENTS],protected,not applicable,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 01:08:42,,1321111448,7/12/2014 01:07:50,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],of the affected limb by poliomyelitis,[CAUSES],20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 01:51:19,,1321127233,7/12/2014 01:49:36,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[CAUSES],[CAUSES],affected,another meaning for affected could be causes,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 03:03:02,,1321154916,7/12/2014 03:02:36,instagc,1,13763729,USA,,,75.182.89.225,[LOCATION],[LOCATION],JOINTS of the affected limb OSTEOARTHRITIS,N/A,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 03:31:47,,1321165857,7/12/2014 03:29:47,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[PREVENTS],[PREVENTS],JOINTS affected limb poliomyelitis protected from development OSTEOARTHRITIS,prevents,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 03:39:35,,1321168778,7/12/2014 03:38:35,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[PREVENTS],[PREVENTS],JOINTS are protected from development of OSTEOARTHRITIS,N/A,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 04:07:28,,1321180509,7/12/2014 04:06:39,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[SYMPTOM],[SYMPTOM],JOINTS affected OSTEOARTHRITIS,N/A,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 06:35:43,,1321231207,7/12/2014 06:35:22,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[LOCATION],[LOCATION],JOINTS,N/A,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 07:48:29,,1321256563,7/12/2014 07:46:45,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM] [SIDE_EFFECT],"[SYMPTOM]
[SIDE_EFFECT]",affected development,N/A,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 07:54:09,,1321258453,7/12/2014 07:52:54,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[SYMPTOM],[SYMPTOM],affected poliomyelitis protected,n/a,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540315,7/12/2014 07:58:46,,1321260076,7/12/2014 07:57:24,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],of the affected limb,n/a,20,103,26,117,1,RO-disease_has_primary_anatomic_site,902353-FS1,It is said that the JOINTS of the affected limb by poliomyelitis are protected from the development of OSTEOARTHRITIS,JOINTS,OSTEOARTHRITIS
502540316,7/11/2014 23:52:38,,1321074355,7/11/2014 23:52:19,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 00:11:09,,1321084676,7/12/2014 00:10:57,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],treatment,n/a,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 00:26:57,,1321093610,7/12/2014 00:26:12,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],can also be used to treat certain forms of,n/a,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 00:32:22,,1321096415,7/12/2014 00:31:15,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],CHRONIC HEPATITIS VIRUS INFECTION,N/A,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 00:32:29,,1321096447,7/12/2014 00:31:49,instagc,1,13763729,USA,,,75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,N/A,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 00:50:07,,1321104103,7/12/2014 00:47:44,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[ASSOCIATED_WITH],[ASSOCIATED_WITH],can be used to treat certain forms,can be used to treat certain forms,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 01:37:17,,1321123504,7/12/2014 01:36:45,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],used as the basis for treatment CHRONIC HEPATITIS C VIRUS INFECTION CHRONIC HEPATITIS B VIRUS INFECTIONS.,n/a,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 01:57:04,,1321129657,7/12/2014 01:56:17,prodege,1,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],treatment of CHRONIC HEPATITIS C VIRUS INFECTION and CHRONIC HEPATITIS B VIRUS INFECTIONS.,N/A,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 02:25:00,,1321141427,7/12/2014 02:24:19,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[TREATS],[TREATS],is now used as the basis for treatment,Stated above,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 03:34:11,,1321166674,7/12/2014 03:33:06,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS],[TREATS],Recombinant IFN alpha is used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and also used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,N/A,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 03:35:41,,1321167404,7/12/2014 03:35:27,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],treat,N/A,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 03:53:48,,1321174510,7/12/2014 03:51:51,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEPATITIS C VIRUS INFECTION treat certain forms CHRONIC HEPATITIS VIRUS INFECTIONS.,because they both are treated by the same drug,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 04:43:41,,1321193345,7/12/2014 04:42:00,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,N/A,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 06:30:40,,1321229554,7/12/2014 06:29:45,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[NONE],[NONE],N/A,No relation,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540316,7/12/2014 08:00:06,,1321260561,7/12/2014 07:59:39,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],treatment,n/a,147,64,183,99,-1,RO-has_causative_agent,903762-FS1,Recombinant IFN alpha is now used as the basis for treatment of CHRONIC HEPATITIS C VIRUS INFECTION and can also be used to treat certain forms of CHRONIC HEPATITIS B VIRUS INFECTIONS.,CHRONIC HEPATITIS B VIRUS INFECTIONS,CHRONIC HEPATITIS C VIRUS INFECTION
502540317,7/11/2014 23:54:35,,1321075328,7/11/2014 23:53:42,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],For treatment,n/a,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 00:04:02,,1321080513,7/12/2014 00:03:40,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[TREATS],[TREATS],drug of choice,n/a,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 00:05:13,,1321081201,7/12/2014 00:05:02,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],others,not sure,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 00:18:08,,1321088874,7/12/2014 00:17:09,instagc,1,13763729,USA,,,75.182.89.225,[OTHER],[OTHER],URETHRAL OR RECTAL GONORRHEA CDC IM CEFTRIAXONE is drug of choice for pharyngeal infections.,N/A,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 00:31:15,,1321095808,7/12/2014 00:29:56,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],drug of choice,N/A,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 00:43:55,,1321101835,7/12/2014 00:43:19,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treatment,not applicable,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 00:47:47,,1321103289,7/12/2014 00:45:28,quickrewards,1,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],drug of choice for pharyngeal infections.,N/A,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 01:59:46,,1321130575,7/12/2014 01:59:27,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],drug of choice,n/a,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 02:07:04,,1321133353,7/12/2014 02:06:09,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[TREATS],[TREATS],treatment of uncomplicated,This tells you the treatments for the following sickness/disease,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 04:36:19,,1321190801,7/12/2014 04:33:15,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone,N/A,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 06:20:06,,1321225816,7/12/2014 06:19:02,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[TREATS],[TREATS],drug of choice,n/a,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 07:57:23,,1321259636,7/12/2014 07:56:22,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],drug of choice,n/a,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 08:21:45,,1321267055,7/12/2014 08:21:39,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],is,da,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 08:35:00,,1321271707,7/12/2014 08:34:30,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540317,7/12/2014 09:19:31,,1321285795,7/12/2014 09:18:49,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[TREATS],[TREATS],treatment,N/A,41,128,69,142,1,RO-may_treat,907845-FS1,"For treatment of uncomplicated cervical, URETHRAL OR RECTAL GONORRHEA CDC and others recommend IM ceftriaxone or oral cefixime; IM CEFTRIAXONE is drug of choice for pharyngeal infections.",URETHRAL OR RECTAL GONORRHEA,IM CEFTRIAXONE
502540318,7/12/2014 00:05:01,,1321081104,7/12/2014 00:04:52,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],cure,not sure,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 00:09:21,,1321083669,7/12/2014 00:09:04,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],cure,n/a,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 00:27:43,,1321093958,7/12/2014 00:26:58,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],cure,n/a,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 00:37:14,,1321098870,7/12/2014 00:36:41,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],Removal may cure,N/A,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 00:39:04,,1321099670,7/12/2014 00:36:09,instagc,1,13763729,USA,,,75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION,N/A,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 00:41:20,,1321100712,7/12/2014 00:40:24,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[TREATS],[TREATS],cure,Na,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 01:36:26,,1321123189,7/12/2014 01:36:07,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],may also cure,n/a,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 01:38:57,,1321124104,7/12/2014 01:37:52,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",Removal of PHEOCHROMOCYTOMA cure HYPERTENSION,N/A,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 02:14:50,,1321136734,7/12/2014 02:14:03,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],PHEOCHROMOCYTOMA HYPERTENSION,n/a,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 02:26:46,,1321142193,7/12/2014 02:24:53,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],cure,n/a,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 03:33:52,,1321166557,7/12/2014 03:33:39,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],cure,N/A,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 06:13:04,,1321223284,7/12/2014 06:10:55,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],cure,n/a,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 06:16:09,,1321224448,7/12/2014 06:15:20,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may also cure,N/A,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 07:56:08,,1321259197,7/12/2014 07:55:47,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],also cure,n/a,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540318,7/12/2014 08:13:22,,1321264503,7/12/2014 08:12:13,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],Removal,N/A,42,11,54,27,-1,RO-disease_may_have_finding,902598-FS1,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
502540319,7/11/2014 23:51:41,,1321073910,7/11/2014 23:50:55,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],as a diagnostic test for,N/A,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 00:10:25,,1321084348,7/12/2014 00:10:13,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],diagnostic,N/A,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 00:34:14,,1321097354,7/12/2014 00:33:51,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic test for,n/a,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 00:52:43,,1321105279,7/12/2014 00:52:01,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],as a diagnostic test,as a diagnostic test,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 00:53:23,,1321105478,7/12/2014 00:52:42,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic test,not applicable,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 01:23:58,,1321117625,7/12/2014 01:23:25,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRAVENOUS EDROPHONIUM CHLORIDE diagnostic test for MYASTHENIA GRAVIS,N/A,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 01:36:44,,1321123303,7/12/2014 01:36:28,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],as diagnostic test for,n/a,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 02:01:49,,1321131293,7/12/2014 02:01:03,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],N/A,This is just research,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 02:35:23,,1321145225,7/12/2014 02:34:25,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRAVENOUS EDROPHONIUM CHLORIDE MYASTHENIA GRAVIS,n/a,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 03:21:09,,1321162070,7/12/2014 03:19:56,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,N/A,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 03:56:28,,1321175635,7/12/2014 03:53:37,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],as a diagnostic test for,na,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 04:00:14,,1321177274,7/12/2014 03:59:23,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRAVENOUS EDROPHONIUM CHLORIDE diagnostic test MYASTHENIA GRAVIS,diagnosed by test or drug,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 04:33:13,,1321189738,7/12/2014 04:31:06,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,N/A,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 08:05:10,,1321262127,7/12/2014 08:04:33,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic,n/a,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540319,7/12/2014 08:17:09,,1321265443,7/12/2014 08:16:34,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnostic test,N/A,213,155,230,187,1,RO-may_diagnose,906834-FS1,Maximum velocity and amplitude of repetitive ( 1 per second) 30 degrees saccadic eye movements were quantitatively assessed for 4 minutes before and after INTRAVENOUS EDROPHONIUM CHLORIDE as a diagnostic test for MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,INTRAVENOUS EDROPHONIUM CHLORIDE
502540320,7/12/2014 00:00:50,,1321078539,7/11/2014 23:58:41,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[IS_A],[IS_A],an,n/a,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 00:02:22,,1321079483,7/12/2014 00:01:55,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",an,n/a,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 00:11:47,,1321085061,7/12/2014 00:11:39,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],KERATOSIS,N/A,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 00:27:54,,1321094035,7/12/2014 00:26:57,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],These skin lesions included,N/A,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 00:34:44,,1321097580,7/12/2014 00:34:15,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],an,n/a,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 01:03:20,,1321109289,7/12/2014 01:02:42,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[PART_OF],[PART_OF],included,not applicable,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 01:15:21,,1321114448,7/12/2014 01:14:37,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]","a perianal lesion,",[CAUSES] [MANIFESTATION],86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 01:35:39,,1321122898,7/12/2014 01:34:31,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],These skin lesions included,n/a,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 02:02:47,,1321131660,7/12/2014 02:00:47,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different kinds of skin lesions,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 02:34:21,,1321144877,7/12/2014 02:33:35,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PIGMENTED SEBORRHEIC KERATOSIS ISOLATED PAPULE ON THE FOREARM,n/a,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 03:08:58,,1321157166,7/12/2014 03:08:09,instagc,1,13763729,USA,,,75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],skin lesions included PIGMENTED SEBORRHEIC KERATOSIS ISOLATED PAPULE ON THE FOREARM,N/A,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 03:30:05,,1321165353,7/12/2014 03:29:43,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],an,N/A,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 03:41:10,,1321169416,7/12/2014 03:40:15,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"These skin lesions included an intradermal nevus, PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and acantholytic acanthoma.",N/A,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 04:00:10,,1321177253,7/12/2014 03:59:09,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[SYMPTOM],[SYMPTOM],PIGMENTED SEBORRHEIC KERATOSIS ISOLATED PAPULE FOREARM,N/A,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540320,7/12/2014 04:51:50,,1321196063,7/12/2014 04:50:19,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],skin lesions included PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM,N/A,86,52,116,82,-1,RO-disease_may_have_finding,902798-FS1,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
502540321,7/11/2014 23:56:37,,1321076490,7/11/2014 23:56:19,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],in,n/a,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 00:10:13,,1321084172,7/12/2014 00:10:05,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],circulating,N/A,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 00:10:29,,1321084373,7/12/2014 00:10:14,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],concentrations,n/a,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 01:09:48,,1321111946,7/12/2014 01:08:47,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[SYMPTOM] [LOCATION],"[LOCATION]
[SYMPTOM]",while IgE concentrations,[SYMPTOM] [LOCATION],115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 02:13:57,,1321136241,7/12/2014 02:13:04,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[CONTRAINDICATES],[CONTRAINDICATES],ALLERGY NON ALLERGY,n/a,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 02:21:42,,1321140248,7/12/2014 02:20:37,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],known ALLERGY concentrations NON ALLERGY,very confused here,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 03:05:12,,1321155667,7/12/2014 03:04:31,instagc,1,13763729,USA,,,75.182.89.225,[CONTRAINDICATES],[CONTRAINDICATES],volunteers with known ALLERGY NON ALLERGY sufferers,N/A,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 03:27:38,,1321164623,7/12/2014 03:27:15,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[NONE],[NONE],N/A,opposite,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 03:41:50,,1321169643,7/12/2014 03:41:11,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[PREVENTS],[PREVENTS],Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY,N/A,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 04:09:24,,1321181323,7/12/2014 04:08:28,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[OTHER],[OTHER],concentrations ALLERGY NON ALLERGY,N/A,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 05:04:57,,1321200578,7/12/2014 05:03:46,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],none,no relation; one is the opposite of the other,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 07:56:21,,1321259312,7/12/2014 07:55:00,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALLERGY,n/a,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 08:02:52,,1321261481,7/12/2014 08:02:33,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],did not change.,n/a,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 08:12:13,,1321264196,7/12/2014 08:10:33,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[CONTRAINDICATES],[CONTRAINDICATES],sufferers,N/A,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540321,7/12/2014 08:21:04,,1321266784,7/12/2014 08:20:58,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],state,da,115,151,122,162,-1,RO-cause_of,900413-FS1,Acute steady state moderate exercise significantly altered circulating IgE concentrations in volunteers with known ALLERGY while IgE concentrations in NON ALLERGY sufferers did not change.,ALLERGY,NON ALLERGY
502540322,7/12/2014 00:11:00,,1321084620,7/12/2014 00:10:38,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],opportunistic,N/A,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 00:29:56,,1321095077,7/12/2014 00:29:28,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used to identify,n/a,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 00:31:48,,1321096118,7/12/2014 00:31:14,instagc,1,13763729,USA,,,75.182.89.225,[IS_A],[IS_A],GROUP B STREPTOCOCCAL INFECTIONS Group B streptococcus (STREPTOCOCCUS AGALACTIAE,N/A,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 00:34:02,,1321097278,7/12/2014 00:33:09,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],causes serious infections,N/A,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 01:32:33,,1321121618,7/12/2014 01:31:57,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],an opportunistic pathogen which causes serious infections,n/a,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 01:34:02,,1321122298,7/12/2014 01:33:31,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",GROUP B STREPTOCOCCAL INFECTIONS identify (STREPTOCOCCUS AGALACTIAE,N/A,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 01:51:04,,1321127132,7/12/2014 01:49:35,prodege,1,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],history of GROUP B STREPTOCOCCAL INFECTIONS and laboratory tests used identify (STREPTOCOCCUS AGALACTIAE,N/A,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 03:28:12,,1321164785,7/12/2014 03:27:54,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],laboratory tests,N/A,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 03:36:00,,1321167554,7/12/2014 03:34:33,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE which causes serious infections in newborn infants and compromised patients in other age groups.,N/A,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 04:06:39,,1321180076,7/12/2014 04:06:00,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],STREPTOCOCCAL INFECTIONS tests streptococcus (STREPTOCOCCUS AGALACTIAE,N/A,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 08:07:02,,1321262712,7/12/2014 08:04:59,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],streptococcus an opportunistic pathogen,n/a,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 08:22:17,,1321267186,7/12/2014 08:22:11,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],(STREPTOCOCCUS,da,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 08:30:58,,1321270422,7/12/2014 08:30:34,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 09:21:23,,1321286372,7/12/2014 09:20:43,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[PART_OF],[PART_OF],identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE,N/A,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540322,7/12/2014 10:18:30,,1321305511,7/12/2014 10:17:24,vivatic,1,25451531,GBR,,,83.67.28.193,[IS_A],[IS_A],Group B streptococcus,N/A,147,49,171,81,-1,RO-has_causative_agent,903802-FS1,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
502540323,7/12/2014 00:05:59,,1321081629,7/12/2014 00:05:43,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],with,not sure,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 00:06:56,,1321082158,7/12/2014 00:06:21,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],evaluated in 30 patients with,N/A,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 00:08:47,,1321083275,7/12/2014 00:08:28,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],evaluated,n/a,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 00:33:24,,1321096929,7/12/2014 00:32:51,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],were evaluated with,n/a,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 01:00:28,,1321108209,7/12/2014 00:59:49,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],injection,not applicable,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 01:27:54,,1321119519,7/12/2014 01:26:29,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],HYPERTHERMIA were evaluated patients with HEPATOCELLULAR CARCINOMA,N/A,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 02:11:22,,1321135080,7/12/2014 02:09:51,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],combined with,n/a,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 02:20:36,,1321139713,7/12/2014 02:20:05,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],N/A,It is related to nothing,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 03:25:20,,1321163742,7/12/2014 03:23:37,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[NONE],[NONE],N/A,I am unable to find a relation.,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 03:33:25,,1321166478,7/12/2014 03:33:09,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combined,N/A,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 03:57:36,,1321176112,7/12/2014 03:56:29,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combined with HYPERTHERMIA,na,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 03:57:48,,1321176168,7/12/2014 03:56:00,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],HYPERTHERMIA evaluated 30 patients with HEPATOCELLULAR CARCINOMA,treats,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 04:11:15,,1321182256,7/12/2014 04:10:14,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTHERMIA evaluated 30 patients HEPATOCELLULAR CARCINOMA,N/A,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 06:11:33,,1321222807,7/12/2014 06:10:34,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],were evaluated in,N/A,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540323,7/12/2014 07:56:52,,1321259460,7/12/2014 07:56:32,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],results of,n/a,392,440,404,464,1,RO-disease_may_have_finding,902839-FS1,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
502540324,7/11/2014 23:50:09,,1321073252,7/11/2014 23:49:19,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[IS_A],[IS_A],called,n/a,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 00:10:03,,1321084117,7/12/2014 00:09:54,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],called,N/A,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 00:10:31,,1321084385,7/12/2014 00:10:10,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],called a,n/a,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 00:35:21,,1321097910,7/12/2014 00:34:03,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],called,N/A,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 00:46:30,,1321102765,7/12/2014 00:45:16,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[CAUSES],[CAUSES],develops,Na,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 01:14:33,,1321114115,7/12/2014 01:13:49,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],called,[DIAGNOSE_BY_TEST_OR_DRUG],36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 01:30:45,,1321120775,7/12/2014 01:29:52,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[IS_A],[IS_A],SOLID MASS OF LEUKEMIA CELLS called GRANULO CYTIC OR MYELOID SARCOMA,N/A,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 01:31:56,,1321121353,7/12/2014 01:31:26,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],called a GRANULO CYTIC OR MYELOID SARCOMA,n/a,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 01:52:54,,1321127927,7/12/2014 01:51:21,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],develops,LEUKEMIA CELLS could be associated with GRANULO CYTIC OR MYELOID SARCOMA?,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 01:55:49,,1321129167,7/12/2014 01:55:25,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],called,n/a,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 02:12:59,,1321135767,7/12/2014 02:12:00,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],A SOLID MASS OF LEUKEMIA CELLS GRANULO CYTIC OR MYELOID SARCOMA,n/a,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 03:26:05,,1321164021,7/12/2014 03:25:21,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES],[CAUSES],a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called GRANULO CYTIC OR MYELOID SARCOMA,N/A,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 03:30:21,,1321165399,7/12/2014 03:30:06,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[IS_A],[IS_A],called,N/A,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 04:40:09,,1321192282,7/12/2014 04:38:15,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA,N/A,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540324,7/12/2014 06:24:40,,1321227394,7/12/2014 06:24:06,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],called a,N/A,36,76,66,108,1,RO-disease_has_finding,901709-FS1,"Rarely, a patient with AML develops A SOLID MASS OF LEUKEMIA CELLS called a GRANULO CYTIC OR MYELOID SARCOMA (chloroma.",A SOLID MASS OF LEUKEMIA CELLS,GRANULO CYTIC OR MYELOID SARCOMA
502540325,7/11/2014 23:51:06,,1321073644,7/11/2014 23:50:50,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],treat,n/a,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 00:31:36,,1321096010,7/12/2014 00:31:12,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],immunosuppressive drug,n/a,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 00:35:40,,1321098090,7/12/2014 00:35:22,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],used to treat,N/A,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 00:39:36,,1321099882,7/12/2014 00:39:05,instagc,1,13763729,USA,,,75.182.89.225,[CONTRAINDICATES],[CONTRAINDICATES],AZATHIOPRINE used to treat RHEUMATOID ARTHRITIS,N/A,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 00:44:35,,1321102047,7/12/2014 00:44:07,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[TREATS],[TREATS],treat,Na,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 00:53:33,,1321105550,7/12/2014 00:52:51,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",immunosuppressive drug used to treat,immunosuppressive drug used to treat,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 01:00:48,,1321108342,7/12/2014 01:00:29,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treat,not applicable,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 01:40:14,,1321124448,7/12/2014 01:39:52,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS],[TREATS],AZATHIOPRINE used to treat RHEUMATOID ARTHRITIS,N/A,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 05:02:14,,1321199248,7/12/2014 05:01:44,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],AZATHIOPRINE is used to treat RHEUMATOID ARTHRITIS,N/A,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 06:26:06,,1321227837,7/12/2014 06:25:36,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[TREATS],[TREATS],used to treat,N/A,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 07:55:17,,1321258930,7/12/2014 07:54:46,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],used to treat,N/A,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 08:00:03,,1321260550,7/12/2014 07:58:48,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treat,n/a,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 08:01:01,,1321260925,7/12/2014 08:00:43,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],used to treat,n/a,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 08:20:49,,1321266695,7/12/2014 08:20:43,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],AZATHIOPRINE,da,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540325,7/12/2014 08:32:11,,1321270854,7/12/2014 08:31:41,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],used to treat,n/a,64,0,84,12,1,RO-may_treat,908261-FS1,AZATHIOPRINE is an immunosuppressive drug that is used to treat RHEUMATOID ARTHRITIS,RHEUMATOID ARTHRITIS,AZATHIOPRINE
502540326,7/12/2014 00:09:39,,1321083864,7/12/2014 00:09:22,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],treated,n/a,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 00:11:08,,1321084675,7/12/2014 00:10:43,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],with combination therapy of,N/A,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 00:52:41,,1321105269,7/12/2014 00:51:54,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treated with,not applicable,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 01:01:34,,1321108709,7/12/2014 01:00:48,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[TREATS],[TREATS],treated with combination therapy,[TREATS],167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 01:59:27,,1321130494,7/12/2014 01:58:42,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treated with,n/a,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 02:10:48,,1321134901,7/12/2014 02:08:32,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],FLUTAMIDE 250 mg HIRSUTISM,n/a,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 03:29:11,,1321165096,7/12/2014 03:28:55,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],therapy,N/A,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 03:51:05,,1321173321,7/12/2014 03:50:31,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],rapid and marked reduction,na,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 05:09:52,,1321202505,7/12/2014 05:08:47,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],combination therapy FLUTAMIDE twice daily rapid marked reduction HIRSUTISM,treats,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 06:23:32,,1321226956,7/12/2014 06:22:34,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],had a rapid and marked reduction in their score.,N/A,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 07:58:35,,1321259985,7/12/2014 07:58:22,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],treated,n/a,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 08:21:11,,1321266833,7/12/2014 08:21:05,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],their,da,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 08:22:31,,1321267246,7/12/2014 08:20:47,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],therapy,n/a,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 08:34:29,,1321271521,7/12/2014 08:34:16,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],women combination of FLUTAMIDE,n/a,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540326,7/12/2014 09:20:21,,1321286027,7/12/2014 09:19:57,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[TREATS],[TREATS],treated,N/A,167,65,176,74,1,RO-may_treat,907497-FS1,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
502540327,7/12/2014 00:05:30,,1321081331,7/12/2014 00:05:14,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],leukaemia,not sure,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 00:09:32,,1321083795,7/12/2014 00:09:07,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],"included ALL,",n/a,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 00:26:56,,1321093596,7/12/2014 00:26:14,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 00:34:33,,1321097481,7/12/2014 00:33:59,instagc,1,13763729,USA,,,75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma,",N/A,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 00:47:34,,1321103230,7/12/2014 00:46:32,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluation,Na,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 01:03:46,,1321109458,7/12/2014 01:02:11,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"included ALL, acute myeloid leukaemia (AML), Hodgkin's disease,",[DIAGNOSE_BY_TEST_OR_DRUG],175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 01:36:06,,1321123042,7/12/2014 01:35:39,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],Diagnosis specific malignancies available for evaluation,n/a,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 01:37:24,,1321123549,7/12/2014 01:36:35,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],evaluation included OSTEOSARCOMA RETINOBLASTOMA,N/A,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 02:24:52,,1321141383,7/12/2014 02:23:46,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,list of malignancies,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 02:32:45,,1321144227,7/12/2014 02:31:54,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[PART_OF],[PART_OF],OSTEOSARCOMA RETINOBLASTOMA,n/a,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 03:34:53,,1321166981,7/12/2014 03:34:28,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[NONE],[NONE],N/A,Two different diseases,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 03:38:35,,1321168414,7/12/2014 03:37:49,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]","Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system tumours and hepatoblastoma.",N/A,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 04:46:10,,1321194407,7/12/2014 04:44:52,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],Diagnosis specific malignancies available for evaluation included OSTEOSARCOMA RETINOBLASTOMA,N/A,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 08:01:54,,1321261178,7/12/2014 08:00:47,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],malignancies included,n/a,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540327,7/12/2014 08:03:26,,1321261670,7/12/2014 08:02:53,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[IS_A],[IS_A],"evaluation included ALL,",n/a,175,203,187,217,-1,RO-has_manifestation,906321-FS1,"Diagnosis specific malignancies available for evaluation included ALL, acute myeloid leukaemia (AML), Hodgkin's disease, NHL, rhabdomyosarcoma, neuroblastoma, retinoblastoma, OSTEOSARCOMA Wilms' tumour, RETINOBLASTOMA Ewings' sarcoma, central nervous system (CNS) tumours and hepatoblastoma.",OSTEOSARCOMA,RETINOBLASTOMA
502540328,7/11/2014 23:50:49,,1321073513,7/11/2014 23:50:22,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],treated with,n/a,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 00:08:27,,1321083096,7/12/2014 00:08:12,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],treated,n/a,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 00:10:35,,1321084421,7/12/2014 00:10:26,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],DOPA,N/A,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 00:25:08,,1321092707,7/12/2014 00:24:15,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],treated,n/a,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 00:47:52,,1321103304,7/12/2014 00:46:51,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treated,not applicable,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 00:51:58,,1321104860,7/12/2014 00:51:22,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",chronically treated with,chronically treated with,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 01:37:52,,1321123701,7/12/2014 01:37:25,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",PARKINSON'S DISEASE chronically treated with L DOPA,N/A,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 02:00:45,,1321130876,7/12/2014 01:59:47,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],chronically treated with,n/a,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 02:01:16,,1321131115,7/12/2014 02:00:12,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],PARKINSON'S DISEASE L DOPA,n/a,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 03:23:36,,1321163127,7/12/2014 03:21:53,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES] [TREATS],"[TREATS]
[CAUSES]",Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA,N/A,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 03:38:01,,1321168216,7/12/2014 03:37:12,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],chronically treated with L DOPA,na,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 03:38:05,,1321168231,7/12/2014 03:37:07,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],PARKINSON'S DISEASE chronically treated with L DOPA,treats,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 04:37:28,,1321191307,7/12/2014 04:36:20,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],PARKINSON'S DISEASE chronically treated with L DOPA,N/A,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 06:35:20,,1321231022,7/12/2014 06:34:47,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],chronically treated,N/A,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540328,7/12/2014 07:59:38,,1321260395,7/12/2014 07:59:19,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],treated,n/a,51,96,70,102,1,RO-may_treat,908224-FS1,"Dyskinesias occur in the majority of patients with PARKINSON'S DISEASE chronically treated with L DOPA and also occur in several nonhuman primate species after 1 methyl 4phenyl 1,2,3,6 tetrahydropyridine (MPTP) and L DOPA treatment.",PARKINSON'S DISEASE,L DOPA
502540329,7/11/2014 23:56:17,,1321076307,7/11/2014 23:55:55,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],may be a useful experimental model for,n/a,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 00:07:51,,1321082749,7/12/2014 00:07:31,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],may be,n/a,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 00:44:11,,1321101926,7/12/2014 00:42:21,instagc,1,13763729,USA,,,75.182.89.225,[SYMPTOM],[SYMPTOM],SPONTANEOUSLY ELEVATED BP may be useful experimental human HYPERTENSION,N/A,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 00:59:48,,1321107969,7/12/2014 00:57:42,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],experimental model,not applicable,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 01:33:30,,1321122025,7/12/2014 01:32:22,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SPONTANEOUSLY ELEVATED BP model for human HYPERTENSION,N/A,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 02:02:36,,1321131610,7/12/2014 02:01:21,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SPONTANEOUSLY ELEVATED BP,n/a,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 03:31:18,,1321165695,7/12/2014 03:30:05,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION,N/A,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 03:32:07,,1321165944,7/12/2014 03:31:41,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[MANIFESTATION],[MANIFESTATION],model,N/A,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 03:53:36,,1321174438,7/12/2014 03:51:06,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],particular types of,na,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 04:41:59,,1321192758,7/12/2014 04:40:10,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION,N/A,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 04:59:44,,1321198462,7/12/2014 04:58:03,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[OTHER],[OTHER],green monkeys SPONTANEOUSLY ELEVATED BP may useful experimental model particular types human HYPERTENSION,other - experiment on animals to benefit humans,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 06:22:28,,1321226595,7/12/2014 06:21:26,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[SYMPTOM],[SYMPTOM],particular types,n/a,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 08:05:41,,1321262320,7/12/2014 08:02:57,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],SPONTANEOUSLY ELEVATED BP,N/A,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 08:22:46,,1321267367,7/12/2014 08:22:40,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[LOCATION],[LOCATION],HYPERTENSION,da,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540329,7/12/2014 08:22:53,,1321267398,7/12/2014 08:22:32,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],useful experimental model,n/a,67,158,92,170,-1,RO-has_definitional_manifestation,904583-FS1,"Taken together, these data suggest that African green monkeys with SPONTANEOUSLY ELEVATED BP may be a useful experimental model for particular types of human HYPERTENSION",SPONTANEOUSLY ELEVATED BP,HYPERTENSION
502540330,7/11/2014 23:49:17,,1321072816,7/11/2014 23:46:40,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[OTHER],[OTHER],decreased,-,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 00:06:05,,1321081670,7/12/2014 00:05:43,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],treatment,n/a,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 00:36:39,,1321098569,7/12/2014 00:36:20,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],treatment with,N/A,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 00:54:38,,1321106062,7/12/2014 00:54:13,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treatment with,not applicable,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 01:02:08,,1321108862,7/12/2014 01:01:37,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",decreased during treatment,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 02:03:06,,1321131807,7/12/2014 02:01:49,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[TREATS],[TREATS],decreased during treatment,SYMPTOMATIC URINARY TRACT INFECTION can be treated with  METHENAMINE HIPPURATE,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 02:17:56,,1321138227,7/12/2014 02:16:47,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treatment with,n/a,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 03:33:08,,1321166364,7/12/2014 03:32:52,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],treatment,N/A,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 03:40:14,,1321169037,7/12/2014 03:39:37,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,N/A,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 03:58:15,,1321176321,7/12/2014 03:57:37,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],treatment with,na,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 04:13:38,,1321183448,7/12/2014 04:13:07,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[TREATS],[TREATS],SYMPTOMATIC URINARY TRACT INFECTION treatment METHENAMINE HIPPURATE,N/A,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 04:56:12,,1321197506,7/12/2014 04:55:36,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],SYMPTOMATIC URINARY TRACT INFECTION during treatment with METHENAMINE HIPPURATE,N/A,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 06:15:20,,1321224086,7/12/2014 06:12:25,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],treatment with,Symptomatic urinary tract infection is treated by Methenamine hippurate.,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 07:55:46,,1321259057,7/12/2014 07:55:10,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[SIDE_EFFECT]",INFECTION during treatment,n/a,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540330,7/12/2014 08:08:21,,1321263099,7/12/2014 08:07:53,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treatment,N/A,17,90,52,111,1,RO-may_prevent,907215-FS1,The incidence of SYMPTOMATIC URINARY TRACT INFECTION also decreased during treatment with METHENAMINE HIPPURATE,SYMPTOMATIC URINARY TRACT INFECTION,METHENAMINE HIPPURATE
502540331,7/11/2014 23:54:43,,1321075426,7/11/2014 23:54:24,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],difficult to control,n/a,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 00:11:24,,1321084815,7/12/2014 00:11:10,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 00:13:50,,1321086328,7/12/2014 00:13:23,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in the differential diagnosis of,N/A,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 00:31:10,,1321095794,7/12/2014 00:30:33,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],This case,n/a,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 00:45:15,,1321102299,7/12/2014 00:44:37,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[CAUSES],[CAUSES],diagnosis,Na,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 01:02:41,,1321109036,7/12/2014 01:01:58,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,not applicable,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 01:25:48,,1321118446,7/12/2014 01:24:55,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",PHEOCHROMOCYTOMA to control HYPERTENSION,N/A,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 01:57:22,,1321129806,7/12/2014 01:56:11,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PHEOCHROMOCYTOMA HYPERTENSION,n/a,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 02:22:50,,1321140664,7/12/2014 02:21:43,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[PREVENTS],[PREVENTS],need to consider PHEOCHROMOCYTOMA,need to consider Pheochromocytoma before it changes its stages,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 03:55:16,,1321175142,7/12/2014 03:54:07,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],PHEOCHROMOCYTOMA difficult to control HYPERTENSION,manifestation,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 04:14:24,,1321183813,7/12/2014 04:13:40,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[TREATS],[TREATS],PHEOCHROMOCYTOMA to control HYPERTENSION,N/A,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 07:58:21,,1321259907,7/12/2014 07:58:00,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis control HYPERTENSION,n/a,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 08:10:32,,1321263722,7/12/2014 08:09:50,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 08:20:56,,1321266752,7/12/2014 08:20:50,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],demonstrates,da,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540331,7/12/2014 08:23:54,,1321267713,7/12/2014 08:23:23,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],typical presentation of pheochromocytoma,n/a,194,91,206,107,1,RO-disease_may_have_finding,902961-FS1,This case demonstrates a typical presentation of pheochromocytoma and the need to consider PHEOCHROMOCYTOMA early in the differential diagnosis of hypertensive emergency or difficult to control HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
502540332,7/11/2014 23:51:35,,1321073884,7/11/2014 23:51:07,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 00:11:27,,1321084841,7/12/2014 00:11:09,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],showed both and,N/A,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 00:11:58,,1321085147,7/12/2014 00:11:49,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],biopsies,N/A,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 00:19:53,,1321089762,7/12/2014 00:19:23,instagc,1,13763729,USA,,,75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both ADENOMATOUS POLYPS and large POLYPOID MASSES,N/A,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 00:29:26,,1321094820,7/12/2014 00:28:57,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],biopsies showed both,n/a,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 00:41:40,,1321100866,7/12/2014 00:41:04,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],mixture,not applicable,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 00:54:22,,1321105936,7/12/2014 00:53:35,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were diagnosed,were diagnosed,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 01:34:03,,1321122302,7/12/2014 01:33:33,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],showed both ADENOMATOUS POLYPS and large POLYPOID MASSES,n/a,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 02:05:09,,1321132625,7/12/2014 02:03:49,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ADENOMATOUS POLYPS POLYPOID MASSES,n/a,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 02:07:36,,1321133576,7/12/2014 02:06:53,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,two different conditions,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 02:14:38,,1321136611,7/12/2014 02:13:50,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],N/A,there is no relation option for this,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 03:31:40,,1321165815,7/12/2014 03:31:23,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both and,N/A,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 05:02:58,,1321199613,7/12/2014 05:02:15,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[OTHER],[OTHER],ADENOMATOUS POLYPS and POLYPOID MASSES,N/A,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 05:31:35,,1321210108,7/12/2014 05:29:33,prodege,1,28083307,CAN,BC,Vancouver,70.79.66.85,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both,N/A,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540332,7/12/2014 06:34:44,,1321230866,7/12/2014 06:34:27,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,117,88,132,106,-1,RO-disease_may_have_finding,902522-FS1,"Although initial biopsies were diagnosed as juvenile polyps, later biopsies showed both ADENOMATOUS POLYPS and large POLYPOID MASSES with a mixture of juvenile and adenomatous features.",POLYPOID MASSES,ADENOMATOUS POLYPS
502540333,7/11/2014 23:58:39,,1321077349,7/11/2014 23:55:36,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],a patient with,n/a,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 00:03:04,,1321079928,7/12/2014 00:02:51,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],with,n/a,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 00:42:48,,1321101347,7/12/2014 00:41:21,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[TREATS],[TREATS],downsloping,Na,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 00:44:33,,1321102044,7/12/2014 00:43:56,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,not applicable,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 00:55:15,,1321106262,7/12/2014 00:54:24,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test a patient,test a patient,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 01:33:10,,1321121859,7/12/2014 01:32:52,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test a patient with PRINZMETAL ANGINA,n/a,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 02:37:51,,1321145944,7/12/2014 02:37:14,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ERGONOVINE PRINZMETAL ANGINA,n/a,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 03:29:30,,1321165189,7/12/2014 03:29:13,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],test,N/A,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 03:42:40,,1321169989,7/12/2014 03:41:51,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented beat to beat in V5, progressed to ST upsloping with typical angina.",N/A,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 04:02:45,,1321178456,7/12/2014 04:02:16,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ERGONOVINE PRINZMETAL ANGINA,N/A,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 07:45:55,,1321255780,7/12/2014 07:44:35,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,N/A,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 08:10:26,,1321263711,7/12/2014 08:09:49,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,n/a,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 08:21:19,,1321266904,7/12/2014 08:21:12,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],ERGONOVINE,da,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 08:31:40,,1321270704,7/12/2014 08:31:00,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presented,n/a,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540333,7/12/2014 09:55:49,,1321298274,7/12/2014 09:54:25,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],with,none,38,7,55,17,1,RO-may_diagnose,906606-FS1,"During ERGONOVINE test a patient with PRINZMETAL ANGINA presented (in I, aVL, V3 V6) ST downsloping which, after a temporary phase of alternative normalization (AST) beat to beat in V5, progressed to ST upsloping with typical angina.",PRINZMETAL ANGINA,ERGONOVINE
502540334,7/12/2014 00:03:39,,1321080237,7/12/2014 00:03:21,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],of over,n/a,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 00:05:42,,1321081420,7/12/2014 00:05:30,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],urine,not sure,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 01:20:15,,1321116145,7/12/2014 01:19:38,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",BACTERIURIA BACTERIA,N/A,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 01:33:32,,1321122059,7/12/2014 01:33:11,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],of over 10(3) BACTERIA per ml urine,n/a,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 02:31:50,,1321143909,7/12/2014 02:30:58,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BACTERIURIA BACTERIA,n/a,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 02:33:45,,1321144660,7/12/2014 02:32:35,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[PART_OF],[PART_OF],of,n/a,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 03:10:46,,1321157967,7/12/2014 03:10:07,instagc,1,13763729,USA,,,75.182.89.225,[PART_OF],[PART_OF],BACTERIURIA of over 10(3) BACTERIA per ml,N/A,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 03:36:17,,1321167683,7/12/2014 03:35:57,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[CAUSES],[CAUSES],of over,N/A,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 03:37:09,,1321167920,7/12/2014 03:36:24,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[NONE],[NONE],N/A,I cannot find a relation.,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 03:40:41,,1321169247,7/12/2014 03:39:44,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],patients with BACTERIURIA of over 10(3) BACTERIA,manifestation,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 04:48:45,,1321195141,7/12/2014 04:47:48,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[IS_A],[IS_A],with BACTERIURIA of over 10(3) BACTERIA per ml,N/A,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 06:31:36,,1321229905,7/12/2014 06:30:41,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[PART_OF],[PART_OF],of over 10(3),N/A,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 07:59:01,,1321260163,7/12/2014 07:58:36,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[OTHER],[OTHER],studied.,n/a,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 08:09:49,,1321263525,7/12/2014 08:08:22,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[IS_A],[IS_A],of,N/A,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540334,7/12/2014 08:21:31,,1321266966,7/12/2014 08:21:21,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],from,da,75,49,83,60,-1,RO-has_causative_agent,903858-FS1,Organisms which were isolated from patients with BACTERIURIA of over 10(3) BACTERIA per ml of urine regardless of grade of pyuria were studied.,BACTERIA,BACTERIURIA
502540335,7/11/2014 23:57:01,,1321076680,7/11/2014 23:56:39,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],"(hay fever, asthma, ATOPIC DERMATITIS)",n/a,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 00:09:59,,1321084083,7/12/2014 00:09:41,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared,n/a,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 00:11:09,,1321084679,7/12/2014 00:11:01,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],determined,N/A,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 00:12:20,,1321085431,7/12/2014 00:12:03,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[IS_A],[IS_A],ATOPIC,N/A,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 00:19:22,,1321089468,7/12/2014 00:19:02,instagc,1,13763729,USA,,,75.182.89.225,[IS_A],[IS_A],ATOPIC DISEASES ATOPIC DERMATITIS),N/A,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 00:56:14,,1321106659,7/12/2014 00:55:17,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosed allergies,not applicable,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 02:08:29,,1321133916,7/12/2014 02:07:05,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"Using standardised computer assisted face to face interviews,",Using computer assisted face to face interviews they were able to test about allergies,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 02:09:50,,1321134470,7/12/2014 02:07:37,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[PART_OF],[PART_OF],diagnosed ATOPIC DISEASES,n/a,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 02:38:57,,1321146314,7/12/2014 02:37:58,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC DISEASES ATOPIC DERMATITIS),n/a,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 03:27:28,,1321164564,7/12/2014 03:26:06,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES",N/A,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 03:35:07,,1321167101,7/12/2014 03:34:14,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[PART_OF],[PART_OF],"to ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS)",part of,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 06:17:16,,1321224805,7/12/2014 06:16:10,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[IS_A],[IS_A],(hay DERMATITIS),N/A,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 07:46:43,,1321256000,7/12/2014 07:45:56,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,N/A,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 08:02:15,,1321261247,7/12/2014 08:01:55,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATOPIC,n/a,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540335,7/12/2014 08:04:32,,1321261964,7/12/2014 08:04:05,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],doctor diagnosed,n/a,160,124,177,139,-1,RO-cause_of,900308-FS1,"Using standardised computer assisted face to face interviews, we determined and compared the prevalence of doctor diagnosed ATOPIC DISEASES (hay fever, asthma, ATOPIC DERMATITIS) in the study subjects and veterinarian diagnosed allergies in their pets.",ATOPIC DERMATITIS,ATOPIC DISEASES
502540336,7/11/2014 23:55:35,,1321075857,7/11/2014 23:54:36,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],with,n/a,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 00:06:22,,1321081825,7/12/2014 00:06:12,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],scintigraphy.,not sure,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 00:21:03,,1321090382,7/12/2014 00:20:22,instagc,1,13763729,USA,,,75.182.89.225,[SYMPTOM],[SYMPTOM],woman with DIARRHEA IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA,N/A,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 00:33:08,,1321096817,7/12/2014 00:32:24,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 00:36:39,,1321098557,7/12/2014 00:36:08,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],with DIARRHEA,n/a,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 00:49:11,,1321103777,7/12/2014 00:47:53,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],studied,not applicable,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 00:56:20,,1321106701,7/12/2014 00:54:30,clixsense,1,15189335,GBR,H9,London,188.29.164.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL",Na,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 01:35:38,,1321122895,7/12/2014 01:34:03,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],DIARRHEA and IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA,N/A,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 02:01:02,,1321130962,7/12/2014 01:59:08,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER] [NONE],"[OTHER]
[NONE]",N/A,This has nothing to do with the relations given. its only studied,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 02:06:20,,1321133106,7/12/2014 02:05:14,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",DIARRHEA IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA,n/a,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 02:19:23,,1321138961,7/12/2014 02:17:57,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different factors considered,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 03:38:49,,1321168500,7/12/2014 03:38:06,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIARRHEA IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA,associated with,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 04:14:54,,1321184049,7/12/2014 04:14:25,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],IMMUNOHISTOCHEMICAL DIAGNOSIS SOMATOSTATINOMA,N/A,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 06:19:02,,1321225450,7/12/2014 06:17:21,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[SYMPTOM],[SYMPTOM],studied,n/a,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540336,7/12/2014 06:29:16,,1321229098,7/12/2014 06:27:31,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and and,N/A,66,92,74,140,1,RO-disease_may_have_finding,902928-FS1,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
502540337,7/11/2014 23:52:18,,1321074163,7/11/2014 23:51:36,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],received,n/a,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 00:02:52,,1321079754,7/12/2014 00:02:23,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],received,n/a,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 00:24:14,,1321092252,7/12/2014 00:23:11,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],received,n/a,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 00:41:48,,1321100924,7/12/2014 00:40:45,instagc,1,13763729,USA,,,75.182.89.225,[OTHER],[OTHER],patients with PHARYNGITIS received 20 mg/kg/day CEFACLOR,N/A,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 01:01:57,,1321108808,7/12/2014 01:01:14,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],received,not applicable,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 01:07:01,,1321110823,7/12/2014 01:06:09,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[TREATS] [CONTRAINDICATES],"[TREATS]
[CONTRAINDICATES]",received 20 mg/kg/day,[TREATS] [CONTRAINDICATES],144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 01:17:48,,1321115290,7/12/2014 01:16:36,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",PHARYNGITIS received CEFACLOR,N/A,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 01:31:01,,1321120898,7/12/2014 01:30:44,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],received 20 mg/kg/day of CEFACLOR,n/a,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 01:59:07,,1321130382,7/12/2014 01:57:40,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[TREATS],[TREATS],Patients with otitis media received approximately 40 mg/kg/day patients with PHARYNGITIS received 20 mg/kg/day,This tells us the treatment given to patients with this certain sickness/disease,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 02:32:07,,1321144018,7/12/2014 02:30:48,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],received,n/a,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 03:30:04,,1321165352,7/12/2014 03:29:21,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS],[TREATS],Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium,N/A,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 03:30:55,,1321165567,7/12/2014 03:30:38,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],received,N/A,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 03:39:42,,1321168832,7/12/2014 03:38:50,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],patients with PHARYNGITIS received mg/kg/day of CEFACLOR,treats,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 03:42:24,,1321169855,7/12/2014 03:41:09,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],received 20 mg/kg/day of CEFACLOR,na,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540337,7/12/2014 04:03:58,,1321178914,7/12/2014 04:03:10,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[TREATS],[TREATS],PHARYNGITIS received 20 mg/kg/day CEFACLOR,N/A,144,181,155,189,1,RO-may_treat,908192-FS1,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
502540338,7/12/2014 00:02:49,,1321079745,7/12/2014 00:02:23,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[SIDE_EFFECT],[SIDE_EFFECT],slowly began again,n/a,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 00:04:27,,1321080808,7/12/2014 00:04:10,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],"disappeared,",not sure,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 00:06:19,,1321081784,7/12/2014 00:05:43,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],treatment,N/A,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 00:10:56,,1321084574,7/12/2014 00:10:45,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],treatment,n/a,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 00:39:19,,1321099755,7/12/2014 00:38:30,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[TREATS],[TREATS],treatment,Na,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 00:58:52,,1321107572,7/12/2014 00:57:44,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"the tremors disappeared, resulted in recurrence",[DIAGNOSE_BY_TEST_OR_DRUG],169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 01:39:51,,1321124369,7/12/2014 01:38:57,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[CAUSES] [TREATS],"[TREATS]
[CAUSES]",treatment with IMIPRAMINE resulted in DEPRESSION.,N/A,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 01:55:02,,1321128865,7/12/2014 01:53:20,prodege,1,17334212,CAN,NB,Fredericton,142.162.42.73,[TREATS],[TREATS],treatment with IMIPRAMINE after noncompliance recurrence of DEPRESSION.,N/A,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 02:03:43,,1321132103,7/12/2014 02:02:41,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],IMIPRAMINE DEPRESSION.,n/a,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 02:13:49,,1321136186,7/12/2014 02:12:50,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]",successful treatment of the patient's depression with IMIPRAMINE but slowly began again,It was treated but then had another side effect,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 03:27:54,,1321164719,7/12/2014 03:27:39,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],treatment,N/A,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 05:01:42,,1321199091,7/12/2014 05:00:26,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],treatment with IMIPRAMINE after drug noncompliance resulted in recurrence of DEPRESSION.,N/A,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 05:07:52,,1321201722,7/12/2014 05:06:55,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[CONTRAINDICATES],[CONTRAINDICATES],IMIPRAMINE tremors slowly began again after drug noncompliance resulted recurrence DEPRESSION.,contraindicates,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 06:33:48,,1321230611,7/12/2014 06:33:03,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SIDE_EFFECT],[SIDE_EFFECT],drug noncompliance resulted in recurrence,N/A,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540338,7/12/2014 07:57:32,,1321259667,7/12/2014 07:57:17,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],treatment,n/a,169,59,179,69,1,RO-may_treat,908350-FS1,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
502540339,7/12/2014 00:04:44,,1321080955,7/12/2014 00:04:04,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[CAUSES],[CAUSES],was evoked by bolus injection of,n/a,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 00:12:01,,1321085183,7/12/2014 00:11:29,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],evoked by,N/A,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 00:37:36,,1321099000,7/12/2014 00:36:43,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[CAUSES],[CAUSES],evoked,Na,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 00:42:53,,1321101405,7/12/2014 00:42:29,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],injection,not applicable,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 01:19:38,,1321115938,7/12/2014 01:19:01,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],ENDOTOXEMIA evoked ESCHERICHIA COLI ENDOTOXIN,N/A,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 01:37:34,,1321123600,7/12/2014 01:37:18,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was evoked by bolus injection of,n/a,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 02:07:23,,1321133471,7/12/2014 02:06:25,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ENDOTOXEMIA ESCHERICHIA COLI ENDOTOXIN,n/a,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 02:16:12,,1321137423,7/12/2014 02:15:26,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[NONE],[NONE],N/A,I am not the smartest person so this sentence was very confusing,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 02:16:46,,1321137674,7/12/2014 02:16:11,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],evoked,n/a,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 03:32:17,,1321166017,7/12/2014 03:31:19,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES],[CAUSES],ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities,N/A,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 07:56:31,,1321259357,7/12/2014 07:56:09,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],evoked,n/a,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 08:08:52,,1321263295,7/12/2014 08:08:30,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],evoked by,n/a,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 08:22:02,,1321267110,7/12/2014 08:21:56,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],cytokine,da,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 08:36:05,,1321272007,7/12/2014 08:35:31,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",was evoked injection,n/a,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540339,7/12/2014 09:22:09,,1321286685,7/12/2014 09:21:48,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[CAUSES],[CAUSES],evoked by bolus injection of,N/A,45,0,71,11,1,RO-has_causative_agent,903581-FS1,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
502540340,7/11/2014 23:54:01,,1321075119,7/11/2014 23:53:23,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PREVENTS],[PREVENTS],prevented,n/a,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 00:06:11,,1321081711,7/12/2014 00:06:00,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],ASTHMA,not sure,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 00:06:45,,1321082053,7/12/2014 00:06:24,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],prevented,n/a,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 00:19:01,,1321089302,7/12/2014 00:18:37,instagc,1,13763729,USA,,,75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SALMETEROL prevented EXERCISE INDUCED ASTHMA,N/A,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 00:35:27,,1321097976,7/12/2014 00:35:08,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[PREVENTS],[PREVENTS],prevented,n/a,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 01:06:06,,1321110480,7/12/2014 01:05:31,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[PREVENTS],[PREVENTS],prevented,[PREVENTS],21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 01:54:23,,1321128633,7/12/2014 01:53:20,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[PREVENTS],[PREVENTS],SALMETEROL EXERCISE INDUCED ASTHMA,n/a,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 02:32:34,,1321144178,7/12/2014 02:32:08,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[PREVENTS],[PREVENTS],prevented,n/a,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 03:30:37,,1321165485,7/12/2014 03:30:21,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[PREVENTS],[PREVENTS],prevented,N/A,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 04:53:32,,1321196660,7/12/2014 04:53:03,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],SALMETEROL prevented EXERCISE INDUCED ASTHMA,N/A,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 06:10:54,,1321222628,7/12/2014 06:10:10,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[PREVENTS],[PREVENTS],prevented,n/a,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 06:34:25,,1321230760,7/12/2014 06:33:49,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],prevented,N/A,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 07:41:39,,1321254487,7/12/2014 07:40:51,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],prevented,N/A,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 08:00:21,,1321260674,7/12/2014 08:00:04,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[PREVENTS],[PREVENTS],prevented,n/a,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540340,7/12/2014 08:05:53,,1321262379,7/12/2014 08:05:31,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[PREVENTS],[PREVENTS],prevented,n/a,21,0,44,10,1,RO-may_prevent,907104-FS1,"SALMETEROL prevented EXERCISE INDUCED ASTHMA in all 13 children studied, at 1, 5, and 9 hours.",EXERCISE INDUCED ASTHMA,SALMETEROL
502540341,7/11/2014 23:54:23,,1321075255,7/11/2014 23:54:03,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[PART_OF],[PART_OF],useful marker in,n/a,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 00:05:42,,1321081421,7/12/2014 00:05:04,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 00:26:11,,1321093237,7/12/2014 00:25:41,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],involving,n/a,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 01:12:58,,1321113434,7/12/2014 01:12:15,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],difficult to discriminate,[DIAGNOSE_BY_TEST_OR_DRUG],168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 01:22:36,,1321117108,7/12/2014 01:21:39,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",HEPATOCELLULAR CARCINOMA diseases involving the LIVER,N/A,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 01:55:57,,1321129217,7/12/2014 01:54:28,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[PART_OF],[PART_OF],HEPATOCELLULAR CARCINOMA LIVER,n/a,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 03:43:06,,1321170151,7/12/2014 03:42:25,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[LOCATION],[LOCATION],involving the LIVER,na,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 03:43:24,,1321170268,7/12/2014 03:42:41,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[NONE],[NONE],N/A,I cannot find a relation.,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 03:51:51,,1321173640,7/12/2014 03:49:36,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[CAUSES],[CAUSES],discriminate it from benign diseases involving the LIVER,Because it says that it may cause that to happen to your liver,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 06:21:57,,1321226463,7/12/2014 06:21:21,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],discriminate it from benign diseases involving,N/A,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 08:01:45,,1321261106,7/12/2014 08:01:23,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[TREATS],[TREATS],involving the,n/a,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 08:08:29,,1321263165,7/12/2014 08:07:03,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],involving the LIVER,n/a,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 08:15:31,,1321264968,7/12/2014 08:13:22,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],involving,N/A,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 08:21:38,,1321267009,7/12/2014 08:21:32,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],although,da,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540341,7/12/2014 08:37:56,,1321272521,7/12/2014 08:37:12,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may possibly,n/a,168,60,173,84,1,RO-disease_has_primary_anatomic_site,902330-FS1,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
502540342,7/12/2014 00:05:42,,1321081423,7/12/2014 00:05:13,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as,n/a,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 00:11:28,,1321084847,7/12/2014 00:11:20,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],conditions,N/A,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 00:33:50,,1321097163,7/12/2014 00:33:25,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[TREATS],[TREATS],"reduced,",n/a,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 00:50:46,,1321104387,7/12/2014 00:49:11,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES],[CAUSES],can result.,not applicable,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 00:57:38,,1321107201,7/12/2014 00:56:15,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]","is reduced,",[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION],37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 01:30:10,,1321120537,7/12/2014 01:29:32,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"is reduced, medical conditions such as ENDOMETRIAL HYPERPLASIA",n/a,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 02:20:03,,1321139423,7/12/2014 02:18:49,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[MANIFESTATION],[MANIFESTATION],medical conditions osteoporosis and ENDOMETRIAL HYPERPLASIA can result.,As stated above,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 02:21:09,,1321139949,7/12/2014 02:19:24,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[PREVENTS],[PREVENTS],"is reduced,",n/a,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 03:34:27,,1321166763,7/12/2014 03:34:06,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 03:37:05,,1321167908,7/12/2014 03:36:17,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[CAUSES],[CAUSES],"FERTILITY reduced, medical osteoporosis ENDOMETRIAL HYPERPLASIA can result.",causes,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 04:03:09,,1321178625,7/12/2014 04:02:46,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[CAUSES],[CAUSES],FERTILITY ENDOMETRIAL HYPERPLASIA,N/A,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 04:57:41,,1321197911,7/12/2014 04:56:50,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],"FERTILITY is reduced, and ENDOMETRIAL HYPERPLASIA can result.",N/A,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 05:29:33,,1321209409,7/12/2014 05:27:59,prodege,1,28083307,CAN,BC,Vancouver,70.79.66.85,[NONE],[NONE],N/A,Both related to menstrual cycle not each other,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 06:16:18,,1321224474,7/12/2014 06:15:07,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"reduced,",n/a,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540342,7/12/2014 07:59:02,,1321260171,7/12/2014 07:56:40,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],"reduced,",N/A,37,107,46,130,-1,RO-disease_may_have_finding,902892-FS1,"When the menstrual cycle is altered, FERTILITY is reduced, and medical conditions such as osteoporosis and ENDOMETRIAL HYPERPLASIA can result.",FERTILITY,ENDOMETRIAL HYPERPLASIA
502540343,7/11/2014 23:54:00,,1321075109,7/11/2014 23:52:41,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for control of,n/a,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 00:03:27,,1321080146,7/12/2014 00:03:17,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],control,not sure,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 00:09:02,,1321083463,7/12/2014 00:08:49,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],control,n/a,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 00:09:33,,1321083810,7/12/2014 00:09:10,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[TREATS],[TREATS],for control of,N/A,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 00:40:23,,1321100209,7/12/2014 00:39:20,clixsense,1,15189335,GBR,H9,London,188.29.164.133,[TREATS],[TREATS],control,Na,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 01:04:32,,1321109813,7/12/2014 01:03:49,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",for control,[PREVENTS] [TREATS],86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 01:36:07,,1321123048,7/12/2014 01:35:39,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION,N/A,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 01:49:35,,1321126753,7/12/2014 01:47:24,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[SYMPTOM],[SYMPTOM],INFLAMMATION,Inflamation is a symtop,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 02:16:11,,1321137419,7/12/2014 02:15:56,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],control of,n/a,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 03:29:43,,1321165278,7/12/2014 03:29:31,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],control,N/A,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 03:46:26,,1321171521,7/12/2014 03:45:49,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[TREATS],[TREATS],Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION,N/A,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 03:57:26,,1321176028,7/12/2014 03:56:02,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PREDNISOLONE ACETATE control POSTOPERATIVE INFLAMMATION,N/A,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 05:08:46,,1321202065,7/12/2014 05:07:52,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],PREDNISOLONE ACETATE control of POSTOPERATIVE INFLAMMATION,treats,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 06:20:49,,1321226093,7/12/2014 06:19:11,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],for control of,N/A,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540343,7/12/2014 07:54:45,,1321258728,7/12/2014 07:53:14,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[PREVENTS],[PREVENTS],for control of,N/A,86,50,112,70,1,RO-may_treat,907986-FS1,Diclofenac sodium was found to be as effective as PREDNISOLONE ACETATE for control of POSTOPERATIVE INFLAMMATION and as effective as flurbiprofen for inhibition of intraoperative miosis.,POSTOPERATIVE INFLAMMATION,PREDNISOLONE ACETATE
502540344,7/12/2014 00:11:19,,1321084723,7/12/2014 00:11:10,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],before,N/A,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 03:32:50,,1321166175,7/12/2014 03:32:22,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[SYMPTOM],[SYMPTOM],shows,N/A,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 04:13:05,,1321183193,7/12/2014 04:12:08,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULOSIS subjects increasing TUBERCULIN SENSITIVITY,N/A,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 05:06:06,,1321201020,7/12/2014 05:04:34,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY,N/A,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 06:27:00,,1321228115,7/12/2014 06:26:06,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[OTHER],[OTHER],the diagnosis shows that,N/A,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 07:56:39,,1321259405,7/12/2014 07:55:18,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 08:04:04,,1321261850,7/12/2014 08:03:28,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reactions of diagnosis TUBERCULOSIS,n/a,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 08:20:35,,1321266621,7/12/2014 08:20:27,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],subjects,da,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 08:24:20,,1321267864,7/12/2014 08:23:55,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULIN,n/a,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 08:35:29,,1321271857,7/12/2014 08:35:01,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],shows the risk groups,n/a,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 09:21:46,,1321286568,7/12/2014 09:21:24,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subjects with increasing,N/A,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 09:54:23,,1321297648,7/12/2014 09:53:03,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[SYMPTOM],[SYMPTOM],increasing,none,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 09:58:59,,1321299350,7/12/2014 09:57:40,prodege,1,21891314,AUS,7,Glen Iris,58.6.248.249,[ASSOCIATED_WITH],[ASSOCIATED_WITH],shows that the risk groups consist of subjects with increasing,N/A,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 10:17:23,,1321305154,7/12/2014 10:16:22,vivatic,1,25451531,GBR,,,83.67.28.193,[TREATS],[TREATS],tuberculin reactions,N/A,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540344,7/12/2014 10:39:06,,1321312274,7/12/2014 10:38:54,instagc,1,27753923,GBR,,,92.40.74.118,[LOCATION],[LOCATION],TUBERCULIN SENSITIVITY,n/a,111,187,123,209,1,RO-may_diagnose,906613-FS1,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
502540345,7/12/2014 00:01:27,,1321078964,7/12/2014 00:01:08,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],consulted for,n/a,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 00:18:37,,1321089090,7/12/2014 00:18:09,instagc,1,13763729,USA,,,75.182.89.225,[SYMPTOM],[SYMPTOM],diagnosis of BRONCHIAL CARCINOMA consulted for HEMOPTYSIS,N/A,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 00:32:50,,1321096667,7/12/2014 00:32:16,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[OTHER],[OTHER],consulted for,n/a,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 01:29:51,,1321120366,7/12/2014 01:28:36,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",BRONCHIAL CARCINOMA consulted for HEMOPTYSIS,N/A,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 01:53:19,,1321128139,7/12/2014 01:52:32,prodege,1,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],diagnosis of BRONCHIAL CARCINOMA consulted for HEMOPTYSIS,N/A,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 02:18:47,,1321138625,7/12/2014 02:17:38,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[LOCATION],[LOCATION],A chest x ray showing large tumor in the left lower lobe,Location is selected because the large tumor is found in the left lower lobe,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 03:40:35,,1321169181,7/12/2014 03:39:37,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],who consulted for,na,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 04:15:37,,1321184330,7/12/2014 04:14:55,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],BRONCHIAL CARCINOMA consulted HEMOPTYSIS,N/A,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 05:06:54,,1321201368,7/12/2014 05:04:58,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BRONCHIAL CARCINOMA consulted for HEMOPTYSIS,associated with,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 06:21:24,,1321226269,7/12/2014 06:20:07,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",consulted,n/a,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 06:29:43,,1321229284,7/12/2014 06:29:18,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[MANIFESTATION],[MANIFESTATION],who consulted for,N/A,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 08:20:26,,1321266573,7/12/2014 08:20:11,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[TREATS],[TREATS],tumor,da,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 08:21:37,,1321266997,7/12/2014 08:21:00,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis consulted,N/A,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 08:23:22,,1321267570,7/12/2014 08:22:54,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],consulted for,n/a,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540345,7/12/2014 08:33:42,,1321271296,7/12/2014 08:32:54,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",smoking who consulted for,n/a,220,138,230,157,1,RO-disease_may_have_finding,902532-FS1,"A chest x ray showing a large tumor like opacity in the left lower lobe and endoscopy visualizing a budding mass suggested a diagnosis of BRONCHIAL CARCINOMA in a 55 year old, tobacco smoking Cambodian who consulted for HEMOPTYSIS and altered general status.",HEMOPTYSIS,BRONCHIAL CARCINOMA
502540346,7/12/2014 00:10:12,,1321084171,7/12/2014 00:10:01,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[SYMPTOM],[SYMPTOM],have,n/a,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 00:20:21,,1321089984,7/12/2014 00:19:53,instagc,1,13763729,USA,,,75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"most persons with EPILEPSY some persons have frequent SEIZURES,",N/A,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 00:23:10,,1321091661,7/12/2014 00:22:18,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[SYMPTOM],[SYMPTOM],"with EPILEPSY some persons have frequent SEIZURES,",n/a,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 01:56:18,,1321129378,7/12/2014 01:54:13,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[OTHER],[OTHER],EPILEPSY,Its just stating a fact of the side affects,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 03:56:01,,1321175437,7/12/2014 03:55:11,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[CAUSES],[CAUSES],"EPILEPSY have frequent SEIZURES,",N/A,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 04:02:10,,1321178139,7/12/2014 04:01:06,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"persons with EPILEPSY frequent SEIZURES,",associated with,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 04:56:49,,1321197685,7/12/2014 04:56:13,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[CAUSES],[CAUSES],"EPILEPSY some persons have frequent SEIZURES,",N/A,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 06:25:35,,1321227707,7/12/2014 06:24:41,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[SYMPTOM],[SYMPTOM],have frequent,N/A,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 08:02:39,,1321261422,7/12/2014 08:02:16,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],seizures in most persons with,n/aq,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 08:20:07,,1321266443,7/12/2014 08:19:13,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 08:22:30,,1321267259,7/12/2014 08:22:25,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[PREVENTS],[PREVENTS],diminished,da,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 08:36:33,,1321272139,7/12/2014 08:36:06,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]","frequent SEIZURES,",n/a,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 09:19:56,,1321285924,7/12/2014 09:19:32,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[SYMPTOM],[SYMPTOM],treatment can prevent,N/A,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 09:56:25,,1321298488,7/12/2014 09:55:51,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[SYMPTOM],[SYMPTOM],have,none,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540346,7/12/2014 09:57:38,,1321298884,7/12/2014 09:56:48,prodege,1,21891314,AUS,7,Glen Iris,58.6.248.249,[ASSOCIATED_WITH],[ASSOCIATED_WITH],some persons have frequent,N/A,107,71,115,79,-1,RO-has_definitional_manifestation,904755-FS1,"Although effective treatment can prevent seizures in most persons with EPILEPSY some persons have frequent SEIZURES, which can lead to brain damage, disability, and diminished quality of life (2,3.",SEIZURES,EPILEPSY
502540347,7/12/2014 00:03:19,,1321080050,7/12/2014 00:03:06,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],relapsing,n/a,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 00:04:41,,1321080906,7/12/2014 00:04:29,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],relapsing,not sure,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 00:06:22,,1321081823,7/12/2014 00:06:06,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,[TREATS],[TREATS],for,n/a,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 01:10:44,,1321112282,7/12/2014 01:09:49,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[TREATS],[TREATS],for relapsing,[TREATS],50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 01:29:31,,1321120201,7/12/2014 01:29:11,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],1A for relapsing,n/a,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 01:31:37,,1321121184,7/12/2014 01:30:46,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",INTERFERON BETA 1A relapsing MULTIPLE SCLEROSIS,N/A,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 02:12:46,,1321135661,7/12/2014 02:11:33,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[MANIFESTATION],[MANIFESTATION],Natalizumab plus INTERFERON BETA 1A for relapsing,I am kind of confused with this one,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 02:34:16,,1321144849,7/12/2014 02:33:46,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],for,n/a,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 02:36:23,,1321145516,7/12/2014 02:35:28,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INTERFERON BETA 1A MULTIPLE SCLEROSIS,n/a,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 03:21:53,,1321162331,7/12/2014 03:21:10,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[OTHER],[OTHER],Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,N/A,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 03:34:05,,1321166652,7/12/2014 03:33:53,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[TREATS],[TREATS],for,N/A,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 03:41:08,,1321169391,7/12/2014 03:40:36,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],for relapsing,na,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 03:55:59,,1321175422,7/12/2014 03:55:17,clixsense,1,6365250,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,treats,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 03:58:20,,1321176363,7/12/2014 03:57:27,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[TREATS],[TREATS],INTERFERON BETA 1A MULTIPLE SCLEROSIS,N/A,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540347,7/12/2014 04:38:13,,1321191611,7/12/2014 04:37:29,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,[TREATS],[TREATS],INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,N/A,50,17,68,35,1,RO-may_treat,907946-FS1,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
502540348,7/12/2014 00:06:32,,1321081938,7/12/2014 00:06:23,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],with,not sure,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 00:37:02,,1321098753,7/12/2014 00:36:41,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],caused,n/a,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 00:40:44,,1321100378,7/12/2014 00:39:37,instagc,1,13763729,USA,,,75.182.89.225,[CAUSES],[CAUSES],LEPROSY caused by MYCOBACTERIUM LEPRAE,N/A,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 01:07:48,,1321111107,7/12/2014 01:07:08,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],caused by chronic infection,[CAUSES],58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 02:33:30,,1321144591,7/12/2014 02:32:51,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],LEPROSY MYCOBACTERIUM LEPRAE,n/a,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 03:33:38,,1321166526,7/12/2014 03:33:26,zoombucks,1,5919735,USA,PA,Lansdale,96.245.83.248,[CAUSES],[CAUSES],caused,N/A,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 03:36:23,,1321167729,7/12/2014 03:36:02,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES],[CAUSES],LEPROSY is caused by chronic infection with MYCOBACTERIUM LEPRAE,N/A,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 06:12:24,,1321223074,7/12/2014 06:11:34,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[ASSOCIATED_WITH],[ASSOCIATED_WITH],caused by with,N/A,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 08:01:22,,1321261042,7/12/2014 08:01:02,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],caused chronic infection,n/a,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 08:09:48,,1321263522,7/12/2014 08:09:20,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],caused by,n/a,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 08:22:38,,1321267322,7/12/2014 08:22:32,neodev,1,17610000,GBR,I2,Manchester,90.200.140.201,[CAUSES],[CAUSES],caused,da,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 08:34:15,,1321271482,7/12/2014 08:33:43,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",caused chronic infection,n/a,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 09:20:42,,1321286135,7/12/2014 09:20:22,instagc,1,28301350,GBR,K4,Plymouth,89.241.102.134,[CAUSES],[CAUSES],caused by,N/A,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 09:56:46,,1321298589,7/12/2014 09:56:20,prodege,1,21891314,AUS,7,Glen Iris,58.6.248.249,[CAUSES],[CAUSES],is caused by,N/A,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540348,7/12/2014 10:19:02,,1321305706,7/12/2014 10:18:32,vivatic,1,25451531,GBR,,,83.67.28.193,[CAUSES],[CAUSES],caused by,N/A,58,0,78,7,1,RO-has_causative_agent,903986-FS1,LEPROSY (hanseniasis) is caused by chronic infection with MYCOBACTERIUM LEPRAE (M. leprae.,MYCOBACTERIUM LEPRAE,LEPROSY
502540349,7/12/2014 00:03:16,,1321080021,7/12/2014 00:02:55,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],forming,N/A,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 00:09:49,,1321083959,7/12/2014 00:09:35,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,[CAUSES],[CAUSES],causative agent,n/a,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 00:28:56,,1321094550,7/12/2014 00:28:30,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,[CAUSES],[CAUSES],causative agent,n/a,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 00:29:54,,1321095040,7/12/2014 00:28:16,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],causative agent of,N/A,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 00:43:18,,1321101572,7/12/2014 00:42:54,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES],[CAUSES],causative agent,not applicable,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 01:16:01,,1321114758,7/12/2014 01:15:25,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],the causative agent,[CAUSES],0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 01:28:35,,1321119801,7/12/2014 01:27:38,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],the causative agent,n/a,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 01:57:39,,1321129877,7/12/2014 01:56:20,neodev,1,15825691,CAN,BC,Surrey,96.48.129.199,[CAUSES],[CAUSES],causative agent of PLAGUE,YERSINIA PESTIS is the causative agent of plague and thats why we get them,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 02:03:28,,1321131984,7/12/2014 02:02:47,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],causative agent,n/a,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 03:34:32,,1321166782,7/12/2014 03:34:12,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,[CAUSES],[CAUSES],YERSINIA PESTIS the causative agent of PLAGUE,N/A,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 04:07:57,,1321180681,7/12/2014 04:07:29,paiddailysurveys,1,11786001,USA,NC,Waxhaw,98.23.92.114,[CAUSES],[CAUSES],YERSINIA PESTIS causative agent PLAGUE,N/A,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 06:22:33,,1321226618,7/12/2014 06:21:58,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[CAUSES],[CAUSES],causative agent of,N/A,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 07:44:34,,1321255335,7/12/2014 07:43:37,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],causative,N/A,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 07:52:27,,1321257878,7/12/2014 07:51:25,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],causative agent of,n/a,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
502540349,7/12/2014 08:02:31,,1321261362,7/12/2014 08:02:13,neodev,1,11051762,NLD,9,Utrecht,87.212.164.10,[CAUSES],[CAUSES],causative,n/a,0,39,15,45,1,RO-has_causative_agent,903744-FS1,YERSINIA PESTIS the causative agent of PLAGUE has a feature of forming multicellular aggregates at liquid air interface around the wall of glass tube.,YERSINIA PESTIS,PLAGUE
